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Anterior gradient-2 (AGR2), S100A4, and osteopontin (OPN) play important roles in malignant progression of breast cancer. Their possible involvement in prostate cancer had not been full explored previously. The aim of this study was to investigate the expression status of these genes and their diagnostic and prognostic significance in prostate cancer. The possibility of using these candidate genes as targets to suppress tumourigenicity of prostate cancer cells was also investigated.  

Comparing with the normal and benign cells, expression of AGR2, S100A4 and OPN were greatly increased in malignant prostate cancer cell lines as observed in breast cancer.  Immunohistochemical staining of an archival set of more than 100 prostate tissue samples showed that the levels of all these 3 proteins were significantly higher in carcinoma tissues than those expressed in normal and benign tissues. Kaplain Mire Survival analysis of immunohistochemically stained samples showed that high expression of AGR2 and OPN but not S100A4 was significantly correlated with the poor patients’ survival time. Thus, all these three molecules were over-expressed in prostate carcinomas and AGR2 and OPN may be useful prognostic markers to predict patient’s outcomes. 
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CHAPTER ONE: GENERAL INTRODUCTION 





In the UK, one in three people develop cancer during their lives. The total number is increasing every year.
In 2007, 245,300 new case of malignant cancer (excluding non-melanoma skin cancer) were reported in England: 123,100 cases in males and 122,200 in females. Breast, lung, colorectal and prostate cancers accounted for more than half of the total number of cases. Especially, breast cancer accounted for 31 percent of cases among women and prostate cancer for 25 percent among men. (Fig 1.1) 


Figure 1.1: Incidence of the major cancers, 2007, England
http://www.statistics.gov.uk/CCI/nugget.asp?ID=915
Source: Office for National Statistics (ONS)
The data show that the age-standardised incidence of cancer increased by around 21 percent in males and 45 percent in females between 1971 and 2007. (www.statistics.gov.uk)





The trend of male cancer incidence in the UK has changed in the past number of years. Prostate cancer, accounting for 24% of total cancer cases, exceeds that of lung cancer at 15%, to become the most common cancer in UK males (Fig 1.2). In the UK, over 35,000 prostate cancer cases were diagnosed in 2006. While 35,500 cases of prostate cancer were reported, 22,300 cases of lung cancer were reported as second. Bowel cancer also accounts for 14%. The three most common cancers in men: prostate, lung and bowel, account for over half (53%) of the cancer incidence reported in men in the UK. (CRUK, 2006)
Figure 1.2: The 10 most common cancers in males, UK, 2006
http://info.cancerresearchuk.org/cancerstats/incidence/males/
Source: CRUK




Prostate cancer incidence increases steeply with age. In accordance with the general trend of cancer incidence within the UK population, prostate cancer incidence rate is 144 per 100,000 for men aged 55-59; it rises to 500 by age 65-69, and rises further to 789 by 85+ (Fig 1.3).







World wide, more than 670,000 men were diagnosed with prostate cancer in 2002, accounting for 1/9 of all new cancers in males. Unlike in the UK prostate cancer is the most common male cancer; it is the second most common in men after lung cancer worldwide. Three-quarters of all new cases are in the developed world with the highest rates occurring in North America and the lowest rates in Asian countries. (Fig 1.4)

Figure 1.4: age-standardised incidence and mortality rates for prostate cancer by world regions, 2002 estimates
http://info.cancerresearchuk.org/cancerstats/types/prostate/incidence/
Source: CRUK




During the last ten years in the UK, European age-standardised rate for prostate cancer has increased by a third from 71 per 100,000 in 1997 to 97 per 100,000 in 2006 while the number of the cases diagnosed rose from 23,741 in 1997 to 35,515 in 2006, an increase of 50%. (Fig 1.5) 

Figure 1.5: Age standardised (European) incidence rates, prostate cancer, UK, 1993-2006
http://info.cancerresearchuk.org/cancerstats/types/prostate/incidence/
Source: CRUK
Time trends for a longer period (1975-2006) are shown in Fig 1.6 for Great Britain. During the late 1970s and 1980s rate rose consistently, and an acceleration of the trend in the early 1990s was followed by a brief levelling off in the mid-1990s. Another rising trend is seen in the late 1990s.





1.1.3	 Mortality of prostate cancer

Though there has been a huge rise in prostate cancer incidence over the past years this has not been reflected in mortality rates.
In 2006, there were 10,038 deaths in the UK from prostate cancer which accounts for around 12 % of male death from cancer and is the second most common cause of caner death in men after lung cancer.
In older men aged 85+, prostate cancer overtakes lung cancer to become the most common cause of cancer deaths. (Fig1.7)

Figure 1.7: number of deaths and age-specific mortality rates, prostate cancer, UK, 2007
http://info.cancerresearchuk.org/cancerstats/types/prostate/mortality/
Source: CRUK
Worldwide, although North America ranks first in terms of incidence, it is 8th for mortality with the highest rates being recorded in the Caribbean. (Fig 1.4) 
In results by PSA is not only higher prostate cancer incidence but also a much higher proportion of early stage cases being diagnosed which naturally leads to higher survival rates and lower mortality rates relative to the incidence.
Overall in Great Britain, prostate cancer mortality was fairly stable during the 1970s but began to increase in the early 1980s. (Fig 1.6) 

1.1.4	Risk factors of prostate cancer









As with all cancers, a positive family history is a known risk factor. Risk increases two to three fold for men with a first-degree relative diagnosed with prostate cancer. If the relative is less than 60 years old at diagnosis or more than one relative is affected (at any age), the individual’s risk is four times the average. If these factors combine so that when more than one relative is affected by early-onset prostate cancer, the risk is increased seven-fold4, 5.
Interestingly, a strong family history of breast cancer may also affect a man’s risk of prostate cancer, particularly if the family members were diagnosed under the age of 60., Gremlin mutations in the breast cancer susceptibility genes, especially, BRCA1 and BRCA2, can predispose men to prostate cancer6.




Variation in incidence rates around the world and within countries suggests that risk is affected by ethnicity.
In the UK, data shows that black Caribbean and black African men have the highest risk of being diagnosed or dying from prostate cancer which was approximately two to three times than white men9, 10. Meanwhile, Asian men have a lower risk than the national average9. (CRUK, 2005)
Worldwide, the highest rate was also recorded in Caribbean and African American men who have much higher rates than white Americans and Europeans, the lowest incidence is seen in Far East and Asian men11.
However, migrant studies suggest that environmental factors are also involved as the rates for migrants from low to high risk countries increase. Nevertheless, cancer data indicates that ethnic factors are the more important determinants rather than environmental factors. For example, South Asian men living in the UK have a higher risk of prostate cancer than men living in South Asia12.

1.1.5	Pathology of prostate cancer

1.1.5.1	Anatomy of the prostate

The prostate is a pear-shaped exocrine glandular organ enveloped by fibro-muscular connective tissue, composed of an inner layer of smooth muscle, and an outer fibrous condensation13.
It produces secretions which nourish sperm and is an accessory gland of the male reproductive system adding to the bulk of the seminal fluid like seminal vesicles and bulbourethral glands. 
A healthy prostate measures 4 cm transversely at the base (width), 3cm vertically (length) and 2 cm anteroposteriorly (thickness). Its average weight is 8 mgs.14
It is comprised of three distinct zones 15 as shown in Fig 1.8:
The peripheral zone (PZ): 70% of volume, the commonest site for PIN and adenocarcinoma.
The central zone (CZ): 25% of volume.
The transition zone (TZ): 5% of volume, primary site for BPH and the rare large dust carcinoma.

Figure 1.8: Schematic of prostate gland depicts zonal anatomy.16 
(Permitted by American Journal of Roentgenology)
1.1.5.2	BPH

Benign, nodular, paraurethral hyperplasia of the prostate (BPH) is one of the most common disease of elderly men and the most frequent benign condition identified in the prostate. It is the result of proliferation of the mesenchymal-stromal and the glandular epithelial components of the prostate. BPH is not a malignant lesion or a precursor of prostate cancer17.
Normally, BPH appears not to result in the formation of prostatic malignancy since 70%-80% of prostate carcinoma develops in the PZ. Only 20% of all carcinomas are found in the TZ and are usually highly differentiated incidental carcinomas.15
Though there are some similarities between prostate cancer and BPH such as androgenic stimulation requirement, age-prevalence increase and most prostate cancer patients already had BPH17. 




The precursor of prostatic adenocarcinoma has been studied and focused on the prostatic intraepithelial neoplasia (PIN) recently. PIN is considered proliferation of the luminal epithelium with pre-existing acini and ducts and is cytologically atypical and demonstrates features such as nuclear and nucleolar enlargement. It co-exists with cancer in more than 85% of cases but retains an intact or fragmented basal cell layer, unlike cancer, which lacks a basal cell layer.15
PIN was divided into two grades, low-grade PIN and high-grade PIN, according to their features of cellular crowding, nuclear enlargement, and chromatin pattern and nucleolar appearance15.
PIN has a high predictive value as a marker for adenocarcinoma, particularly the high-grade PIN. If this lesion is identified, close surveillance and follow-up biopsy are indicated15, 20, 21.
Thus, current recommendations from the World Health Organization are only reporting high-grade PIN.

1.1.5.4	Grading the prostate cancer

Histological grading methods are very important to assess diagnosis and prognosis in prostate cancer. Many grading systems15 have been proposed in which the Gleason grading system of prostate carcinoma is the predominant and the most commonly used one around the world.
In 1966 DF Gleason developed his unique grading system for prostatic carcinomas based solely on the architectural pattern of tumor in a study of 270 patients from the Minneapolis veterans Administration Hospital22. The Gleason grading system was then expanded to 1032 men by Gleason and the Veteran Administration Cooperative Urological research Group (VACURG) by 197423. A modified Gleason grading system was introduced in 2005, at the ISUP (International Society of Urological Pathology) consensus conference held in San Antonio24. Gleason grading is now both the world wide grading system for prostatic carcinomas and grading system of the WHO tumour classification of prostatic carcinomas.
In the Gleason grading system, the histological patterns were categorized at low magnification according to the extent of glandular differentiation and the pattern of growth of the tumors within the prostatic stroma. The glandular patterns were identified from well-differentiated (grade1) to anaplastic (grade 5) according to the characteristic morphological appearances shown in Table1.1 and Fig 1.924. 




Figure 1.9: Schematic diagram of modified Gleason grading system24
Another innovative aspect of this system was, rather than assigning the worst grade as the grade of the carcinoma, the grade was defined as the sum of the two most common grade patterns and reported as Gleason score25.
For example, the lowest possible Gleason score is 2 (1+1), where both the primary and secondary patterns have a Gleason grade of 1 while the highest possible Gleason score is 10 (5+5), when the primary and secondary patterns both have the most disordered Gleason grades of 5.
The Gleason grading system has been simplified by compressing the scores into ‘grade lumping’ as three groups: well differentiated (Gleason score 2-5), moderately differentiated (6-7) and poorly differentiated (8-10). Combined Gleason scores were commonly used as the prognostic indicators for prostatic carcinomas and correlated with all of the important pathologic parameters and clinical outcomes, such as patient survival time, prostate-specific antigen (PSA), androgen-receptor (AR) and multiple prognostic index15. Recent studies also showed that with the modified Gleason system, grade, stage, tumor extent and serum PSA have good correlations and characterize the difference between low and high grade malignancy of prostate carcinoma26.

1.2	Biomarkers for prostate cancer

1.2.1	Molecular pathology of prostate cancer

The molecular pathology of prostate cancer is complex as many genes are involved in its pathogenesis. A number of somatic mutations and chromosomal abnormalities have been identified in prostate cancer, including overexpression of oncogenes, such as bcl-2 and underexpression of tumor suppressor genes, such as GSTP1, and changes in the expression of growth factors and their receptors27.

1.2.2	Current prognostic biomarkers for prostate cancer





Prostate-specific antigen (PSA) is a 33-kD glycoprotein that is currently the most important tumor marker for adenocarcinoma.
PSA was identified and characterized from 1966 to 197829. The 6-kb PSA gene is located on chromosome 19 and codes for a single-chain 33-kD glycoprotein30. 
PSA is an enzyme that belongs to the kallikrein family of serine protease and also known as human kallikrein 3. Its physiologic function is to liquefy seminal coagulum by cleaving the protein semenogelin into small peptides thus increasing sperm motility15. PSA was initially thought to express specifically in the prostate, especially to benign and malignant prostatic luminal epithelial cells. However, so far, it has been found expressing in several tissues and disease from periurenthral glands to breast carcinoma15.
PSA is normally secreted from prostatic epithelial cells. PSA levels may be elevated in men with prostate cancer because PSA production is increased and because tissue barriers between the prostate gland lumen and the capillary are disrupted, releasing more PSA into the serum31.
The traditional cut off point for an abnormal PSA level in the major screening studies has been 4.0 ng/ml32.At this level, the sensitivity of PSA has been estimated to be about 70 to 80 percent, while the specificity is about 60 to 70 percent estimated33. 




A number of potential biomarkers have been identified and their predictive value to determine the risk of future prostate cancer studied. Transforming growth factor –β1, interleukin-6, PCA3, BRCA and EPCA-2 have been reported and show some predictive value for prostate cancer, but none of them can replace PSA28. Thus, PSA will remain as the most important and effective biomarker for prostate cancer until a more reliable molecular biomarker is identified. 

1.2.3	Some candidate genes to test in my study

In our study, three genes, AGR2, S100A4, OPN, were chosen to test their effectiveness and potential as a prognostic biomarker and therapeutic targets for prostate cancer. They were considered and selected as the candidate genes because:
1)	All have shown a possible role as prognostic indicators with therapeutic potential in breast cancer which is a hormone responsible cancer, the same as the prostate cancer.
2)	AGR2 has previous been investigated without regards to prostate cancer. However the others, like OPN, have been investigated less and produced conflicting results, due to ineffective methods or small sample numbers. 






Anterior gradient-2 (AGR2), a secret protein, is the human orthologue of the secreted Xenopus laevis AGR protein XAG-237. Its molecular weight is 20kDa38, 39. The human AGR2 gene is located on chromosome 7p21.3, a location supported by the sequence of the human genome assembly (NCBI build 35), earlier radiation hybrid mapping and fluorescence in situ hybridization40.
AGR2 was also known as HAG-241 and Gob-442. HAG-2 is the human homologue of the Xenopus laevis cement gland gene XAG-2 which was renamed from DEME-243. It was found co-expressed with estrogen receptor in breast cell line41. Gob-4 was expressed in goblet cells in the intestine. Its deduced amino acid sequence was reported as similar to XAG-2 and it was suggested that Gob may be involved in the secretary mechanism42.




1.3.2	 Role of AGR2 in breast cancer

A number of studies have investigated the role of AGR2 in breast cancer since it was originally observed in breast cancer cell lines. The metastasis-inducing property of AGR2 was first demonstrated by screening of mRNA and protein expression in ER-positive and ER-negative carcinoma. AGR2 was expressed at a higher level in the human breast cancer cell line MCF-7 than in the benign cell line Hama 123. More importantly, transfection of AGR2 cDNA into a benign rat mammary cell line, Rama 37, induced metastasis in vivo, which suggested AGR2 may contribute to the malignant progression of ER-positive breast cancer.48 Subsequent investigation showed that expression of AGR-2 was significantly associated with poor outcome in patients with ER-positive breast cancer, which indicated AGR2 could be used as a prognostic marker for ER-positive breast cancer39. 

1.3.3	 AGR2 in prostate cancer

Unlike its role in breast cancer, the role of AGR2 in prostatic malignancy is not fully understood.
AGR2 was highly induced by androgen in an androgen receptor (AR)-dependent manner and the expression of AGR2 markedly increased at both mRNA and protein levels in prostate cancer cells compared with their benign counterparts, indicating that AGR2 might be involved in the malignant progression of prostate cancer47.






Calcium-binding proteins which act as intracellular calcium receptor molecules and couple changes in intracellular calcium levels to alternations in cell function can be divided into three groups49, according to structural properties:
a)	the calmodulin-S100-tropolin C superfamily, which contain high affinity EF-hand type calcium-binding domains and has approximately 200 family members
b)	those containing a henolysin-like-calcium-binding domain
c)	the annexin family, which bind phospholipids in a calcium-dependent manner 
Human S100 proteins comprise over 20 known members that are distributed tissue specifically and each coded by a separate gene50, 51.
The first two members were identified by Moore in 1965 when a subcellular fraction from bovine brain was isolated. This was thought to contain nervous-system specific proteins. The fraction was called S100 because the constituents were soluble in 100% saturated ammonium sulfphate at neutral pH49, 52. S100A1 and S100B were isolated and characterized from this fraction53, 54. Based on amino acid homology and similar structural properties, several additional proteins have been catalogued to this S100 family49, 51, 55.
The S100 proteins are small, acidic proteins of 10-12 kD and have two distinct EF-hands55, 56.
It is well demonstrated that S100 proteins have been implicated in intracellular and extracellular regulatory activities. Intracellular functional roles of S100 proteins include inhibition of protein phosphorylation, regulation of enzyme activity, regulation of cell growth and differentiation, regulation of calcium homeostasis, regulation of cytoskeleton and regulation of transcriptional factors. The extracellular functions of some S100 proteins are as leukocyte chemoattractants, macrophage activators and modulators of cell proliferation. 55, 57
There has been growing interest in the role of S100 protein family in cancers and several members of S100 family have been shown to play an important roles in tumorgenecity and metastasis, such as S100A258, S100A459, S100A560, S100A661, S100A8, S100A9 and S1001162, 63.




As with most of the S100 family members, S100A4 is a symmetric homodimer stabilized by noncovalent interactions between two helices from each subunit(helices 1,4,1’,4’) that form an X-type four-helix bundle (Fig 1.11).Each S100A4 subunit has two EF-hand calcium-binding domains: a pseudo-EF-hand or S100-hand and a typical EF-hand64, 65,which are brought into close proximity by a small two-stranded antiparallel β-sheet.66 In S100A4, the pseudo-EF-hand is formed by helices 1 and 2. The orientation of helices 3 and 4 in the S100A4 typical EF-hand is similar to S100A665, 67. In S100A4, there is a C-terminal loop following helix 4 that is long and basic, which is particularly unique compared to other S100 proteins65. The main difference between the S100 family proteins is the linker connecting the EF-hands and in the long C-end. Binding of calcium ions by the pseudo-EF-hand induces small conformational alterations in the S100 molecule structure, where as those by the canonical EF-hand result in turning helix 3 relative helix 4, making the hydrophobic amino acid residues of helices 3 and 4, as well as those of the long C-terminal region, more accessible68, 69. This calcium-dependent conformational change is necessary for S100A4 to interact with its protein targets and generate a biological effect and the target binding significantly enhances the calcium binding affinity of S100A464, 65, 67, 70-72. This provides a mechanism for the formation of a high affinity complex in vivo that occurs only when calcium, S100A4, and one of its target proteins are present65.

Figure 1.11: Structure of S100A4
S100A4 , a small 11-kD protein73, 74, was first identified by Jackson-Grusby and coworkers and called 18A2. It was cloned from quiescent fibroblasts following serum stimulation75. S100A4 is expressed in the S phase of the cell cycle49, 75.
It was then identified independently in different laboratories: pEL98, an mRNA induced in transformed murine cells, established from the BALB/C-3T376; 42A, an NGF-induced mRNA in rat pheochromocytoma cells, established from PC12 cells after nerve growth factor stimulation77; p9Ka, an induced protein product in differentiated mammary epithelial stem cells78; mts1, an overexpressed gene product in metastatic tumor cell subclones, the mouse homologue of the rat p9Ka gene73; calvasculin, a protein that interacts with a potent vasorelaxant in bovine aorta79; calcyclin, a protein similar to the EAT protein, purified from mouse stomach 80; CAPL, an protein selectively expressed in cell lines that have been induced to grow or differentiate, purified from bovine neural retina81; FSP1, a filament-associated, calcium-binding protein, detected by in situ hybridization as a postgastrulation event82.

1.4.3	Human S100A4 gene structure

Of 25 currently known human genes of the S100 family, 21 (S100A1-S100A18, trichohylin, filaggrin, and repetin) are located in a cluster in chromosome locus 1q21. Sequencing of the human S100A4 gene showed that it consists of three introns and four exons, the former two of which do not code for an amino acid sequence69.
There are two variants of the human S100A4 as a result of alternative splicing within the 5’-UTR 83. The two splice variants display different expression profiles in human tissues and tumor cell lines84.




S100A4 exerts both intracellular and extracellular effects and is involved in a number of cellular events.

1.4.4.1	Intracellular roles and targets

It has been demonstrated that, using the yeast two-hybrid system, S100A4 could not only exist as a homodimer (S100A4/S100A4) but also form a heterodimer with S100A1 (S100A4/S100A1), another member of S100 family90, 91.
Since S100A4 has not been associated with any enzymatic activity, the interaction with the other target proteins is likely to be more critical for S100A4 activity. S100A4 interacts with the tumor suppressor p5392, nonmuscle myosin II93 and liprin β74, 94.
S100A4 binds to the extreme end of the C terminus of p53 and inhibits the phosphorylation of the tumor suppressor in vitro by protein kinase C (PKC)92. It has been shown that the p53 target gene (p21/WAF, bax, thrombospondin-1 and mdm-2) transcriptions were modulated differently upon S100A4 induction. For example, bax was up-regulated by S100A4, mdm-2 was down-regulated initially and then up-regulated while p21 and thrombopondin-1 were inhibited by S100A492. These seemingly opposite effects of S100A4 expression on p53-regulated genes are not due to the interactions of S100A4 with p53 but likely to be a consequence of direct interactions with other targets such as cytoskeletal proteins65.
S100A4 regulates the monomeric, unassembled state in an isoform-specific manner by binding to the A isoform of the nonmuscle myosin-II (myosin IIA) and then modulate the filament assembly through the stabilization of myosin-II assemblies. S100A4 binds to residues 1909-1924 of the myosin IIA heavy chain, which is near the C-terminal tip of the α-helical coiled-coil.95 Though S100A4 binding site overlap the site of protein kinase C (PKC) at the platelet myosin heavy chain at Ser-191796, recent studies have shown that PKC phosphorylation had no effect on S100A4 binding while the protein kinase CK2 decreased the affinity of S100A497. CK2 phosphorylation of the myosin-IIA heavy chain protects against S100A4-induced filament disassembly97. All data suggest S100A4 regulates cell shape and motility through the modulation of myosin-IIA function65.
S100A4 binds Liprin β1 at the C terminus of Liprin β1 between amino acid residues 938-1005. The S100A4-binding region contains two putative phosphorylation sites by protein kinase C and protein kinase CK2. S100A4-liprin β1 phosphorylation by both kinases in vitro.94

1.4.4.2	Extracellular roles and targets

S100A4 was secreted by fibroblasts in culture and tumor cells can stimulate S100A4 secretion from them98. Furthermore, in vivo, S100A4 was observed accumulating in the blood of aging animals99. 
It was demonstrated that S100A4 protein added to the extracellular space strongly stimulates proteolytic activity of VMR (mouse adenocarcinoma cell line) cells and this activity was associated with matrix metalloproteinases, particularly, with matrix metalloproteinase-13 (MMP-13)98.
In osteosarcoma cells, the mRNA levels of MMP2, membrane type (MT) 1-MMP, and TIMP-1 were significantly reduced when S100A4 mRNA expression was inhibited100. In Madin-Darby canine kidney (MDCK) epithelial cells, the coordinated action of MT1-MMP and S100A4 contributes to the invasion of the malignant carcinoma cells101.
Recent studies have shown that extracellular S100A4 interacts with annexin II, an endothelial plasminogen co-receptor by binding to the N-terminal region. This interaction accelerated plasminogen activation by tissue plasminogen activator on the endothelial cell surface to generate plasmin, which is known to activate pro-MMPs.65, 102
In summary, extracellular S100A4 can promote metastasis by inducing remodeling of the extracellular matrix thus facilitating angiogenesis and tumor invasion.

1.4.5	 Effects of S100A4 in cancers

S100A4 expression is observed in metastatic cancers. Immunohistochemical staining shows S100A4 to be expressed significantly in human breast, pancreatic, prostate, gallbladder, esophagel, gastic, lung, and thyroid carcinomas103-110. In these cancers, S100A4 expression was found at elevated levels compared with normal tissue, suggesting that enhanced S100A4 expression contributes to the manifestation of a metastatic phenotype65.
It has been shown that both intracellular and extracellular S100A4 contributes to the metastasis-promoting function of protein. Possible mechanisms are summarized below in Fig 1.12111.

















An association between S100A4 and cell proliferation has been studied after initial cloning experiments that isolated the S100A4 gene from growth-stimulated cells112, 119. Recent studies have shown that S100A4 expression was associated with an increased amount of p53120. It also suggested that a complex of S100A4 with p53 and the sequestration of p53 may result in stimulation of cells to enter the S phase by abrogating the control functions of p53 at the G1-S checkpoint112, 120, 121.
The regulation of tumor cell populations is a result of an increase in cell numbers by proliferation and balanced by cell loss by apoptosis. Recently it has been reported that S100A4 activates the apoptotic pathway. It might conceivably influence apoptosis by activating more than one signaling system122. 




Another important hallmark of invasive tumour growth and cancer metastasis is angiogenesis. S100A4 has been found to exert its role in angiogenesis particularly by modulating expression of thrombospondin 1 and matrix metalloproteinases (MMPs). 
Thrombospondin 1 belongs to the class of extracellular matrix glycoproteins with antiangiogenic effects that can express the progression of tumours129. In addition, it was demonstrated that the S100A4 oligomer was capable of stimulating angiogenesis by promoting the chemotactic motility of endothelial cells in vitro, and of inducing corneal neovascularisation in vivo74, 98. 
An association between S100A4 and MMPs has previously been described.
Extracellular S00A4 was shown to strongly stimulate proteolytic activity in endothelial and tumour cells, particularly by upregulating MMP13. It was also shown that in a highly metastatic osteosarcoma cell line transfected with a specific ribozyme against the S100A4 gene transcript, the downregulation of S100A4 expression resulted in a reduction of the mRNA levels of MMP2, MMP14 and the endogenous tissue inhibitor TIMP-1100. Recent studies show that the suppression of S100A4 significantly reduced expression and proteolytic activity of MMP9130.

1.4.6	 S100A4 in prostate cancer
S100A4 was first studied in the Dunning R3327 rat prostate cancer model in 1997. The expression of the mRNA and corresponding protein product of S100A4 in 6 different metastatic cell lines of this prostate cancer model was assessed by Western and Northern blotting. There is a direct association between the elevated expression of S100A4 mRNA and protein levels and the increased metastatic capability of individual prostatic cancer cell lines.131
In 2003, S100A4 was studied in the progression of human prostate adenocarcinoma as well as S100A2. The protein level of S100A4 was significantly higher in all carcinoma cells compared to the normal human prostate epithelial cells NHPE and virally transformed prostate epithelial cells P3-HPV-7. The mRNA and protein level of S100A4 was also significantly higher in high-grade cancer specimens compared to BPH, prostatitis, and low-grade cancer. In cancer tissues, the high level of S100A4 observed was correlated with increasing tumour grade using immunohistochemistry. For the first time, the data provided evidence that loss of increased expression of S100A4 may be indicative of cancer progression in human prostate adenocarcinoma.105
Additional studies were carried out to assess the expression of S100A4 during autochthonous prostate cancer progression in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model. It has shown that an increase in the expression of S100A4 at mRNA and protein level in dorsolateral prostate, but not in nontransgenic mice occurred with the progression of age and prostate cancer growth in TRAMP mice. Furthermore, GTP feeding of TRAMP mice resulted in marked inhibition of prostate cancer expression, which was associated with reduction of S100A4 and restoration of E-Cadherin. Thus, S100A4 was suggested as a promising biomarker for prostate cancer.132
The siRNA-mediated suppression of the S100A4 gene was observed to significantly reduce the proliferative and invasive capability of the highly invasive prostate cancer cells PC3. Both MMP-9 and TIMP-1 were found highly responsive to S100A4 gene suppression. It was demonstrated that the S100A4 gene controls the invasive potential of human prostate cancer cells through regulation of MMP-9 and thus contributing to metastasis of prostate cancer cells. S100A4 was suggested to be used as not only a biomarker for prostate cancer progression but also a novel therapeutic or chemopreventive target for treatment.130
However, in contrast to all these data, it was also reported that S100A4 protein was not expressed in benign or malignant prostatic epithelium nor in LNCaP and DU145 cell lines thus suggesting the mechanism underlying the absent S100A4 expression in prostatic epithelium and cell lines may involve methylation133. The difference in the staining pattern from before105 was not due to the differences in the surgical method used for the removal of prostatic tissue, tissue fixation, or the immunohistochemical procedure. The absence of S100A4 protein in cell lines was also not likely to be due to insufficient protein loading since the Western blotting data were in agreement with their immunohistochemical data.




S100A4 is a candidate molecular marker for metastatic potential with high prognostic significance.
S100A4 was first suggested as a prognostic marker in two studies of patients with early stages of breast cancer. Western blotting was used to assess the prognostic significance of S100A4 in primary tumors from a group of 349 patients treated between 1976 and 1982 for stage I and stage II breast cancer. The median survival of the S100A4-negative group was >228 months compared to 47 months for the S100A4-positive group.134
The comparison of S100A4 with other prognostic markers was performed over 14-20 years of immunocytochemically detected S100A4 and other tumor variables in primary tumors from 349 patients with operable breast cancer. Results of this study has shown that in this set of patients, the tumour variable mostly tightly correlated with patient death was S100A4.135
In analogous studies performed on breast cancer, the prognostic significance of protein S100A4 expression has recently been evaluated in a series of cancers. An increase in S100A4 protein expression has been correlated with poor prognosis for patients with colorectal136, gallbladder137, bladder138, esophagel139, non-small-cell lung109, gastric140, medulloblastoma141, pancreatic142 and hepatocellular143 cancer. 59.






Osteopontin (OPN) belongs to the small integrin-binding ligand N-linked glycoprotein (SIBLING) family.
Other members of the SIBLING family are: bone sialoprotein (BSP), dentin matrix protein 1 (DMP1), dentin sialophosphoprotein (DSPP) and matrix extracellular phosphoglycoprotein (MEPE)144, 145.
Members of this family were characterized in bones and teeth146. Chromosomal localization and gene-structure studies suggested that all these SIBLING proteins belong to the same genetic family146.
Three members of the SIBLING family can specifically bind and activate three different MMPs. Activation includes both making the proMMPs enzymatically active and the reaction of the TIMP inhibited MMPs. Using fluorescence binding and affinity purification studies, it has been demonstrated that BSP, DMP1 and OPN activate pro-matrix metalloproteinases (MMP)-2, MMP-9 and MMP-3, respectively, and subsequently bind to the catalytically active MMPs by the abundant serum protein, complement Factor H, thereby, reactivating the inhibition of MMPs.147
Members of the SIBLING family have the capacity to bind and modulate the activity of matrix metalloproteinases (MMPs), and in analyses of nine distinct cancers (breast, colon, stomach, ovarian, lung, rectum, thyroid, kidney and uterus), the elevated expression of SIBLING members were correlated with paired MMP expression148. Furthermore, histological studies showed BSP and OPN were highly expressed in several cancer cells and associated with the tumor grade149. All these studies suggest SIBLINGs as potential markers of early disease progression in a number of different cell types. So far, the role of OPN in the malignant progression of cancer has been more clearly defined than other SIBLINGs.

1.5.2	 OPN
OPN was first discovered by Senger in 1979 as a phosphoprotein secreted by transformed, malignant epithelial cells150 and rediscovered 10 years151 later, by molecular cloning, as a transformation-associated phosphoprotein whose level of expression correlated with tumorgenecity.
OPN was also identified as secreted phosphoprotein I (Spp1), 2ar, uropontin, early T-lymphocyte activation(ETA-1) factor and bone sialoprotein I from the independent investigation from different cell models152, 153.
OPN was expressed in multiple species, such as humans and rodents154, 155 and found in various tissues and cell types including bone, dentin, cementum, hypertrophic cartilage, kidney, brain, activated macrophages, lymphocytes, vascular smooth muscle cells and specialised mammary epithelial cells156-158. Although the secreted protein is present in mineralised connective tissues, it can also be diluted in biological fluids, including blood, milk (lactopontin), urine (uropontin) and seminal fluids159-162.

1.5.3	OPN structure
The comparison of mammalian OPN cDNA from human, mouse, rat, pig, bovine, and chicken samples reveals a high degree of sequence homology at the NH2 and COOH-terminal regions and the 50 amino acid segment152, 155. The single copy OPN gene maps to chromosome 4q13 in humans163 and the human genes consist of seven exons extending approximately 8 kb164. At least three OPN cDNA have been identified because of alternative RNA splicing of the human OPN genes: OPNa (945bp) encoding the full length protein; OPNb (903bp) lacks a 14 amino acid sequence and OPNc (864bp) lacks an additional 27 amino acid sequence165.
Human OPN contains ~314 amino acid residues163, 165 although spice variants have been described. The molecular weight of OPN varies between 41 to 75kD166-170 which could be explained by substantial post-translational modification, including phosphorylation and N-linked glycosylation171.
OPN protein is acidic, hydrophilic and highly negatively charged with features of a secreted protein165. The predicted secondary structure of OPN consists of eight α-helices and six β-sheet segments155 (Fig 1.13). Phosporylation of OPN occurs to a variable extend at up to 28 sites distributed throughout the molecule. It contains ~30 monosaccharides, including 10 sialic acids and carbohydrates present as one N-glycosyl and 5-6 O-glycosyl side chain172.
OPN is rich in aspartate, glutamate and serine residues and contains several interesting structural domains (Fig 1.14): NH2 and COOH-termianl regions, the thrombin cleavage site(RSK) and the Glycine-Arginine-Glycine-Aspartate-Serine(GRGDS) and so on.152 

Figure 1.13: Secondary structure of OPN protein


Figure 1.14: Structure of Osteopontin protein152






It has been demonstrated that in interleukin(IL)-3-treated cells, OPN inhibited apoptosis predominantly through activation of the phosphatidylinositol 3-kinase/Akt pathway178. Stimulation of PI3-kinase activity by OPN binding was shown to regulate activation of osteoclasts179. It was also shown that soluble OPN inhibits apoptosis of adherent human umbilical vein endothelial cells (HUVEC) which grow in an environment without growth factor and cytokines. OPN was also found to inhibit DNA fragmentation and stimulate the expression of the anti-apoptotic protein Bcl-xl in these cells, which suggested that OPN facilitate the survival of stressed endothelial cells by suppressing integrin-mediated death.180
A study on fibroblast survival found OPN protected cardiac fibroblasts from cell death and OPN-deficient cardiac fibroblasts undergo increased H(2)O(2)-induced cell death via caspase-3-independent pathway181. OPN was shown to confer a survival advantage in tumor cells, together with bone sialoprotein (BSP). The initial binding to alpha(v)beta(3) (αvβ3) integrin or CD44 on the cell surface promotes the sequestration of Factor H to cell surface, thus inhibiting the complement-mediated cell death182.




Cell migration and extracellular matrix invasion (ECM) are major steps in cancer cell metastasis. Matrix metalloproteinases (MMPs) degrade the extracellular matrix (ECM) and function in tumor invasion and metastasis.
It has been shown that OPN activates pro-MMP-2 via an NF-kappa-B mediated pathway during ECM invasion184. OPN-induced invasion and migration of human mammary epithelial cells requires urokinase plasminogen activator (uPA)185. The uPA system was found at high levels and uPA consistently predicts poor patient outcome in many cancers186, such as human breast carcinoma and its bone metastasis187.
OPN was also reported to induce phosphorylation and degradation of the inhibitor of nuclear factor Kappa B (I kappa B alpha) by activating I kappa B kinase (IKK), thus inducing the NK kappa b activity. Furthermore, by blocking the IKK/I kappa B alpha signaling pathways, curcumin potently suppressed OPN-induced cell migration, tumor growth, and NF kappa B-mediated pro-MMP-2 activation188.
It was also shown that OPN induction of NF kappa B activity and uPA secretion was PI3’-kinase/Akt/iKK mediated189.
It has been reported in prostate cancer that OPN regulates tumor growth by regulating cyclooxygenase-2 (COX-2). One study demonstrated that induction of COX-2 upregulates prostaglandin E(2) production and activates matrix metalloproteinase-2 (MMP-2) in response to the stimulation of OPN through the protein kinase C alpha/nuclear factor-inducing kinase/nuclear factor-kappa B-dependent signaling pathway190. Meanwhile, in B16F10 cells, another matrix metalloproteinase, MMP-9, was reported to be activated by OPN through MAPK/IKKalpha/beta-dependent NIK/NFκB mediated pathway, thus regulating invasiveness191. Recent studies showed that OPN regulated MMP-2 and uPA activity via integrin-linked kinase (ILK) and AP-1 signaling pathway during tumor cell invasion192. The thrombin-cleaved OPN COOH-terminal fragment has been reported to bind with cyclophilin C or rotamase to the cell surface glycoprotein CD147, thus activating Akt1/2 and MMP-2, and enhancing the invasiveness of tumor cells193.




OPN-induced mammary epithelial cell (MEC) migration was shown to be integrin-dependent and associated with the increase of HGF receptor (Met) mRNA and protein expression and the Met kinase activity suggested OPN-regulated cell migration was hepatocyte growth factor (HGF)-dependent194.
Later studies by the same research group showed OPN-induced migration of MEC was not only HGF-dependent but also epidermal growth factor (EGF) dependent. It was also associated with an increase of EGF receptor (EGFR) mRNA expression and EGFR tysosine kinase activity. 195
Thus, OPN-induced MEC migration includes at least two growth factor/receptor pathways.
It was also reported that OPN-induced cell migration was ERK/MAPK dependent in B16 cells196.

1.5.4.4	Inflammatory and immune response

OPN is involved in the inflammation and immune response197. OPN secreted by activated T cells was expressed in a variety of inflammatory cells including T cells, dendritic cells(DCs), macrophages and NK cells197-199. It induced immune cells, particularly macrophages migrating to sites of inflammation197. Dendritic cells (DCs) were consistently identified as central for T-cell-mediated immunity induction. OPN was found to play a promoting role in the migration of human DCs, activation myeloid-type DCs, augmenting the HLA-DR and adhesion molecules expression, thus promoting maturation of DC towards a T helper 1 (Th1)-promoting phenotype200. OPN was identified as a key cytokine for efficient type-1 immune responses as it was shown that OPN-integrin interaction induced IL-12 secretion while OPN-CD44 interaction suppressed macrophage IL-10 production201.
Two strains of transgenic mice were designed and generated to analyze the role of OPN in immune responses and the results confirmed that OPN plays a vital role in the proliferation and differentiation of B1 cells, enhancing the generation of immunoglobulins202.
Recent studies showed that OPN is also involved in the TLR9 dependent OPN-IFN-alpha pathway in cross-presentation in vitro and anti-herpes simplex virus 1 IFN-alpha response in vivo203.
Nitric oxide (NO) was believed to control blood flow, regulate salt and water balance, play a defending role against tumour cells and infectious microorganisms204. OPN was shown to serve as a defence against NO-mediated host cell cytotoxicity, augmenting the metastatic phenotype204, 205.
Later work demonstrated that OPN inhibited the NO production by macrophage-like RAW264.7 cells and inhibited cytolytic activity of the activated macrophages toward NO-sensitive p815 mastocytoma cells, which suggested the tumour-cell-derived OPN protected the tumour cells from macrophage-mediated destruction206. Interestingly, OPN was also reported to protect tumour cells by interacting with factor H thus enabling cell evasion from complement-mediated cell lysis and opsonisation182. 
However, LPS-induced NO synthesis resulted in feedback inhibition and it was evident that LPS-induced NO synthesis feedback depended on OPN status, thus down regulating iNOS expression207. The heterologous nuclear ribonuclear protein (hnRNP A/B) was identified as a critical NO-dependent trans-regulator of OPN expression in murine macrophages in this model system208.




Angiogenesis, the formation of new blood vessels from the existing ones, is essential for tumor growth and metastasis156. 

1.5.4.5.1	OPN and potent angiogenesis factor VEGF

OPN was reported to be involved in the cooperative mechanisms for VPF/VEGF regulation of EC migration during angiogenesis, with the ανβ3 and thrombin cleavage of OPN together210.
The roles of vascular endothelial growth factor (VEGF) and OPN in angiogenesis was studied and it was apparent that OPN induced endothelial cell migration and upregulated endothelial cell migration was induced by VEGF211. To clarify the cooperative role of VEGF and OPN in angiogenesis, 87 cases of stage I non-small cell lung cancer were detected by immunohistochemistry and it was found that microvessel counts was significantly higher in VEGF and OPN positive tumours. Furthermore, VEGF- and OPN- positive stage I lung adenocarcinoma was significantly related to poor patient survival time compared to others, which indicated that the cooperation of OPN is very important in VEGF-mediated tumour angiogenesis.212












Since OPN was identified as an angiogenic factor by promoting neovascularisation through integrin-mediated endothelial cell migration, prevention of endothelial cell apoptosis and vascular lumen formation145, 215, and integrin-mediated endothelial cell survival was mediated by (via) NF-kB p65 and p50 activity, it was demonstrated that OPN and ανβ3 ligation rapidly increased NF-kB activity and OPN-induced NF-kB activation was dependent on the small GTP-binding protein Ras and the tyrosine kinase Src216.

1.5.5	 OPN in prostate cancer

Prostate cancer is one of the most life-threatening diseases for men worldwide.
OPN was found to contribute to prostate cancer progression217. Messenger RNA blot analysis, immunohistochemistry and Western blot were performed to measure expression of OPN mRNA and protein respectively, in prostate cell lines and it has shown that antibodies against OPN inhibited the anchorage independent growth in prostate cancer cells (LNCaP and C4-2), which suggested OPN may act as a mediator of prostate cancer growth and progression217.
Immunohistochemical staining was also examined in prostate tissues from 34 patients with primary prostate cancer and results showed enhanced OPN expressed in metastatic clinical specimens218.
Enhanced OPN expression was also observed in the serum and plasma of patients with prostate cancer. Interestingly, from studies on clinical specimens and plasma OPN, it was reported that OPN expression showed a negative correlation with patient survival from the study on clinical specimens218.
Anti-ανβ3 integrin antibody (LM609) was used to block the ability of OPN to trigger a Ca2+ transient in PC-3 cells which suggested that OPN was involved in progression of metastatic prostate cancer219.
In addition, OPN was reported to induce the chemotaxis and chemoinvasion of PC-3 cells220.
A study of 2003, measure the level of OPN and BSP expression by immunohistochemistry on 12 breast cases and 9 prostate cases. Though it was limited by the small number of samples, it still showed that the divergent pattern of OPN/BSP expression could be a determinant to characterize bone metastasis of both malignancies.221
OPN expression was also analysed in different prostate cell lines, such as LNCaP222 and PC3223.
TRAnsgenis Mouse Prostate adenocarcinoma (TRAMP) mice was also studied on OPN expression in prostate cancer and by TRAMP testing, dietary genistein was shown to delay the malignant progression by inhibiting OPN expression224.
OPN was also investigated in comparison to other bone markers in prostate cancer patients and it was found that OPN, alone or in combination with bone metastasis, served as prognosticator for survival time in prostate cancer patients225.
OPN was associated with CD44 and MMP9 in migration of prostate cancer cells223. A similar result was obtained from the study in 2008 and the OPN/integrin ανβ3 signaling pathway was involved in the migration and invasion of PC3 cells via regulating the formation and function of invadopodia226.




OPN has been considered as one of the most promising biomarkers for various cancers. The correlation of elevated OPN expression, tumour malignancy and patient survival time has been studied in a variety of cancers. 
A significant increase was observed in OPN plasma concentration in patients with metastatic disease compared with normal sera149, 228. Histological analysis of tumour specimens showed that increased OPN expression was associated with tumour progression in cancers of breast229, stomach230, lung212, 231, prostate217, liver232 and colon233.
Many studies have focused on OPN expression in breast cancer. In 1998, a series of 154, lymph node negative breast cancer patients were analyzed and demonstrated that elevated OPN expression was associated with poorer clinical outcome229. In 2002, it was shown that OPN-negative specimens correlated with a median survival of >228 months while OPN-positive specimens correlated with a median survival of 68 months from 333 patients with operable stage I and II breast cancer thus enforcing the prognostic significance of OPN inhuman breast cancer234.
Intense investigations have been performed on the practical application of plasma OPN biomarkers in clinical medicine. The plasma expression of OPN was examined in both patients with advanced disease and no disease or local/regional disease. These data demonstrated that elevated OPN levels could be sensitive and specific in predicting disease progression in various cancers as shown in Table 1.3145.
Table 1.3 Studies using plasma OPN as a prognostic biomarker
Authors	Journal	Publication year	Cancer type	Number of patients with disease	Number and type of control patients	OPN levels (disease vs control; ng/ml)
Singhal et al.	Clinical Cancer Research	1997	Breast	70	35	142 vs 47
Bramwell et al.	Clinical Cancer Research	2006	Breast	157	n/a	177
Reiniger et al.	American Journal of Opthamology	2006	Uveal melanoma	8	8, healthy	170.72 vs 46.78
Wu et al.	Gut	2007	Gastric cancer	132	93, healthy	166.5 vs 55.6
Le et al.	Clinical Cancer Research	2003	Head and neck squamous cell cancer	54	15, healthy	447 vs 318
Kim et al.	American Journal of Gastroenterology	2006	Hepatocellular carcinoma	62	60, healthy	954 vs 155
Koopman et al.	Cancer Epimediology, Biomarkers & Prevention	2004	Pancreatic adenocarcinoma	50	22, healthy	482 vs 204
Ramankulov et al.	Journal of Cancer Research and Clinical Oncology	2007	Renal cell carcinoma	80	52, healthy	115 vs. 28.9 ug/l
Chang et al.	Lung Cancer	2007	Non-small cell lung cancer	47, Stage IV	32, stage 1	1,58.2 vs 86.2
Ramankulov et al.	The Prostate	2007	Prostate cancer	28, Stage IV	29, healthy	1,723 vs 625 ug/l
Shimada et al.	Oncology	2004	Esophageal squamous cell cancer	103	n/a	>450 vs <450

Furthermore, elevated plasma OPN levels were found to be significantly associated with lower survival rates235. In the study on non-small cell lung cancer, stage was defined as the only independent factor influencing circulating levels of OPN236. In similar analyses on breast cancer, it was shown that measuring OPN levels over the course of breast metastasis enhanced the prognostic value, with an increase in OPN level > 250ng/ml being the strongest prognostic indicator for overall survival237.





































The cell lines used were all single-cell-cloned and their derivation and characterization is summarized in Table 2.1.
Table 2.1 Origins of the human prostate cell lines
Cell lines	Origin	Identity	Reference
PNT2	Human prostate epithelium	Benign	238
LNCaP	Left supraclavicular lymph node metastasis.	androgen-sensitive,adherent epithelial	239
DU145	Brain metastasis.	Epithelial	240
PC3	Bone metastasis	Malignant, neoplastic cells of epithelial origin 	241
PC3M	Selected from PC3	Highly malignant,Epithelial	242


2.2.1.2	Routine culture of cells

All human prostate cells were grown in monolayer culture in RM (routine medium) in T125/T75 tissue culture flasks and maintained in a humidified incubator (model TC2323 CO2 incubator, Borolabs) at 37℃ with 5% (v/v) CO2. Growth medium was changed every 3-4 days.












Frozen cells were removed from liquid nitrogen and thawed quickly in a 37℃ water bath. The cells were transferred to a 25ml universal tube and resuspended in 10ml RM. The cell suspension was then centrifuged at 900rpm for 3 min and the supernatant was discarded. This is to remove all traces of the cryprotectanct DMSO which is toxic to cells when it is above 4℃. The pellet was resuspended in RM and the cell suspension was then transferred to a T75 tissue culture flask and RM was added to give a final suitable volume. Cells were maintained in the humidified incubator with 5% CO2 at 37℃.

2.2.2	Culture of Transfected Cells

After transfection and selection, transfected cells were grown and maintained in the RSM (routine selective medium) in which G418 was added. All the culture methods (passaging, counting, freezing and thawing) were the same as non-transfected cells (Methods 2.1.1) but using RSM instead of RM.

2.2.3	Analysing protein expression in cell lines

Expression of protein was analyzed by Western blotting. 
Western blotting is commonly performed using an anionic detergent (SDS). Dissociated proteins (individual polypeptide subunits) were loaded in a polyacrylamide gel electrophoretic system (PAGE) and were separated according to the size and charge ratio. The separated proteins were then transferred to the nitrocellulose membrane and probed using the specific antibodies.

2.2.3.1	Preparation of cellular extracts





Cells were grown in 9cm dishes and treated as required. Medium was removed and the cells were washed twice with PBS and drained in a sterile situation to get rid of extra PBS. One millilitre boiled(≥95℃) 1×SLB was added to the cell monolayer and the dish was placed on a hot plate (Ori-Block 08-3, Techne) for 3 min. Cells were scraped from the dish using a rubber scraper and transferred to an 1.5ml microfuge tube before being passed through a 16 gauge needle for about 10 times. The protein-containing supernatant was then collected by centrifugation at 4℃ for 10 min. Protein lysates were stored at -80℃. The protein samples would be boiled for 10min, chilled on ice for 2 min and spun down before loading into the SDS gel.

2.2.3.1.2	Using Cellytic M Cell Lysis Reagent with Bradford assay

2.2.3.1.2.1	Using Cellytic M cell Lysis Reagent





The concentration of protein extracted using the method in 2.2.3.1.2.1 was measured using Bio-Rad protein assay (Dye reagent). A standard curve of concentration from 0.03125μg/μl to 1μg/μl BSA in PBS 50μl aliquots was prepared. Protein samples were also diluted for analysis, using appropriate volume of sample diluted to 50μl using PBS. One ml diluted Dye reagent was added to each sample, as well as to the BSA/PBS buffer and PBS blanks, and incubated for 15 min before measuring the absorbance at 595 nm (Multiskan).

2.2.3.1.2.3	Equalization of protein samples for loading





SDS-PAGE was carried out according to the published method243. SDS-PAGE was performed using 4% stacking gel and 9%, 12% or 15% resolving gels respectively, depending on the molecular size of the target protein, using a Bio-Rad mini protein gel system (Bio-rad) in 500 ml of 1× running buffer. The protein samples were electrophoresed at 120V for 15 min to reach the resolving gel and at 200V for 30-45 min according to the position of the dye front. The appropriate protein marker (Lonza) was used to estimate protein sizes. 

2.2.3.3	Transfer of proteins from SDS gel to nitrocellulose membrane

Separated proteins were transferred from the polyacrylamide gel to a nitrocellulose membrane (Hybond-ECL, GE Healthcare) using the Trans-Blot electrophoric transfer system (Flowgen).
Six sheets of Whatman 3MM filter paper and the nitrocellulose membrane were cut according to the gel size and soaked in the 1×transfer buffer. After the SDS-gel electrophoresis, the SDS-gel was also soaked in the chilled 1×transfer buffer for 15 min. A filter paper/gel/membrane sandwich was then assembled in a cassette and the bubbles were squeezed out. The cassette was then placed into a tank containing chilled 1×transfer buffer. The transfer was undertaken at 100V for 2h at 4℃.

2.2.3.4	Coomassie blue and PONCEAU S staining

After transfer, the gel was stained with coomassie blue for an hour and washed with distilled water shaking slowly overnight, then dried using a vacuum gel-drier (Flowgen) at 70℃ for 3 h.
After transfer, the membrane was stained with 10% PONCEAU S solution for 3 min and washed with TBST for 10 min to visualize the protein bands. 
Efficiency of the transfer can be assessed through both staining methods.

2.2.3.5	Immunoblotting for detection of protein expression

The membrane was incubated with 5 ml of 5% Protoblock for 1 h to prevent non-specific binding of the primary antibody. It was incubated with the primary antibody in an appropriate concentration (Table 2.2) at 4℃ overnight. The membrane was then washed 6 times for 5 min with 0.05% TBST and incubated with secondary antibody at appropriate concentration (Table 2.2) for 2 h at the room temperature. Blots were washed 6×5 min with 0.05% TBST again before ECL Advance (GE Healthcare) was performed at 1:1 mixture of reagents I and II. The membrane was incubated with ECL mixture for 1 min at room temperature. After gently discarding the surplus ECL detection reagent, the membrane was sealed in Saran wrap and exposed to the film (GE Healthcare) for a serial required times. The films were developed and fixed in the dark room.

2.2.3.6	Immunoblotting for detection of β-actin expression

Consistently-expressed β-actin antibody was performed to normalise any loading variation. 
After target protein expression detection by ECL, the membrane was washed in 0.1% TBST, agitated overnight. Then the membrane was incubated in 5 ml of 5% Protoblock for 30 min before incubation with the β-actin antibody in a 1:5000 dilution for 30 min. This was followed by three washes with 0.1% TBST for 10 min each and then the secondary antibody was added and incubated for 30 min at room temperature in a 1:1000 dilution. Blots were washed 3×10 min with 0.1% TBST again and bound β-actin probes were visualised using the ECL detection system.
Several different antibodies were used to identify AGR2, S100A4, OPN and β-actin (Table 2.2). All antibodies were diluted in 5% Protoblock.
Table 2.2 Primary and secondary antibodies used in Western blot
Target protein	Primary Antibodies	Secondary antibodies
AGR2	the affinity-purified, in-house rabbit polyclonal anti-human AGR2 1:500	Polyclonal Swine Anti-Rabbit Immunoglobulins/HRP (Dako) 1:1000
S100A4	Polyclonal Rabbit Anti-Human S100A4 (DakoCytomation) 1:500	Polyclonal Swine Anti-Rabbit Immunoglobulins/HRP (DakoCytomation) 1:1000
OPN	MPIIIB10 ascites (OPN)(Developmental Studies Hybridoma Bank) 1:200	Polyclonal Rabbit Anti-Mouse Immunoglobulins/HRP (Dako) 1:1000
β-Actin	Monoclonal Anti-β-Actin (Sigma)1:5000	Polyclonal Rabbit Anti-Mouse Immunoglobulins/HRP (Dako) 1:1000
                                
       
2.2.4	Protein expression in tissues
2.2.4.1	Human tissue samples
Human prostate tissues were an archival set with full treatment history held within Molecular Pathology Laboratory, Department of Pathology, University of Liverpool, UK.
Tissues were taken from 65 prostate adenocarcinoma patients with a mean age of 73 years and from 34 benign prostate hyperplastic (BPH) patients with a mean age of 67.5 years through trans-urethral resection of the prostate in the Royal Liverpool University Hospital during the 5-year period of 1995-2000. Seven normal prostate tissues were taken from road traffic accident victims (mean age 48 years) who did not have a history of any prostatic diseases.




2.2.4.2.1	Preparation of APES((3-Aminopropyl)triethoxy-silane) coated slides

Glass slides were placed in a large metal racks and washed in 1% acid/alcohol solution for 30 minutes. The slides were then rinsed in running tap water for 15 minutes and dried in an incubator at 70℃ overnight. After cooling, the slides were placed in acetone for 10 minutes and transferred to 2% APES in acetone for 10 minutes. Following several washes with distilled water, the slides were dried overnight. 

2.2.4.2.2	Sectioning of tissues with Microtome





Immunohistochemistry (IHC) is the process of localizing proteins in the cells of a tissue section exploiting the principle of antibodies binding specifically to antigens in biological tissues244.
Immunohistochemical staining is widely used in the diagnosis of abnormal cells such as those found in cancerous tumours. In our study, it was used to identify protein expression in human prostate tissues.
Sections were dewaxed in two washes of xylene (each 3 min 30 sec) and rinsed in Industrial Methylated Spirits (IMS) twice (each 30 sec) before being transferred into fresh H2O2 /methanol, in order to block endogenous peroxidase activity for 12 minutes. They were then rinsed in running tap water for 30 sec, and deionised water for 30 sec, the sections were placed in staining racks, and transferred to a pressure cooker filled with EDTA solution (pH7) for 3 min for AGR2 and S100A4 staining or without any pretreatment for OPN. Then all slides were racked into Sequenzer (Immunocytochemistry Staining Trays (Shandon UK)) and washed with Tris Buffered Saline (TBS) for 4 min. Then 100ul 5% BSA/TBS was applied to each section and then incubated with the primary antibody at an appropriate dilution for 1 hour and washed with TBS for 3 times (each 4 min). Bound antibodies were detected with 100μl of Labelled Polymer for each section for 30 minutes and washed in TBS for three times (each 4 min).To visualize the reaction, the samples were stained with DAB for 10 min, washed with distilled water for 4 min, briefly counterstained with Heamatoxylin solution for 2 min, rinsed in 0.5% Acid/alcohol, washed with water and briefly rinsed in Scott’s Tap water until the blue colour appeared on the slides. Sections were dehydrated through four rinses of IMS and cleaned in 3 washes of xylene and mounted in DPX (Bios, Lancashire, UK).
All tissue sections were examined independently under the microscope by two qualified pathologist and classified by Gleason Grade. 
Several different antibodies were used in IHC to identify AGR2, S100A4, and OPN in tissues shown as Table 2.3.
Table 2.3 Antibodies used in IHC
Target protein	Primary Antibodies	dilution
AGR2	the affinity-purified, in-house rabbit polyclonal anti-human AGR2	1:500
S100A4	Polyclonal Rabbit Anti-Human S100A4 (DakoCytomation)	1:500







RNAi (RNA interference) is a process of mRNA cleavage and degradation that is induced by double stranded RNA in a sequence-specific manner.

Figure 2.1 RNAi process

2.2.5.2	Three different ways of RNAi 
   
Figure 2.2 Three ways to trigger the RNAi pathway245

2.2.5.3	RNAi of Vector-based approach














Figure 2.3:  pSilencerTM 4.1-CMV neo vector.




Figure 2.4: Vector-based approach flow chart

2.2.5.3.1	Designing siRNA silencing Construct

Using Ambion’s siRNA target finders in Design Tool, three target sequences were chosen and confirmed by blast searching to ensure it has high specificity only to these target genes. For S100A4, target sequence numbers 7, 11 and 19 (Table 2.4) were chosen for further investigation.  And for OPN, target sequence numbers 1, 18 and 47 (Table 2.4) were chosen for the further investigation. The vector used in the experiment, pSilencerTM 4.1-CMV neo vector, was specified in the design tool. Sense and antisense oligonucleotides of 55 base pairs were designed and ordered from Invitrogen.
Table 2.4:  S100A4 and OPN target sequence and their siRNA silencing constructs.















2.2.5.3.2	Cloning hairpin siRNA into vector

2.2.5.3.2.1	Annealing sense and antisense oligos

Oligos were dissolved and diluted to 1μg/μl in TE buffer. For every construct, 2μl sense oligo was mixed with 2μl antisense oligo in 46μl 1×DNA annealing solution. The mixture was heated at 90℃ for 3 min, cooled at 37℃ and incubated for 1 hr at 37℃. Annealed inserts were stored at -20℃.

2.2.5.3.2.2	Preparation of competent cells

Competent DH5α E.Coli bacteria cells were prepared from stocks for cloning experiments. The DH5α glycerol stocks were streaked onto LB-agar plates and incubated at 37℃ overnight. After 24 hours, a single colony was picked into an individual flask containing 10ml LB medium and incubated overnight at 37℃ with shaking at 225rpm. After overnight incubation, 1ml of culture was added into 100ml of SOB medium containing 1ml Mg2+ salts and incubated at 37℃ with shaking at 225 rpm. After 90 min, the OD was checked at 550nm using SOB as a blank and then checked at regular intervals. When the OD reached 0.4, the culture was divided equally into 8 universals and chilled on ice for 10 min. The cells were pelleted by centrifugation at 2500 rpm for 10 min at 4℃ and the supernatant was discarded. Pellets were resuspended in 66 ml of cold RF1 buffer (RF1 calcium chloride/glycerol buffer) followed by chilling on ice for 10 min and centrifugation for a further 10 min at 2500 rpm at 4℃. The supernatant was discarded and pellets resuspended in a total of 16ml RF2 buffer (RF2 calcium chloride/glycerol buffer) and pooled. The cell mixture was then divided into 1 ml aliquots in cryovials, flash frozen in liquid nitrogen and stored in -80℃. 

2.2.5.3.2.3	Ligation of silencing inserts into pSilencer plasmid

The pSilencerTM 4.1-CMV plasmids were supplied linearlized and ligation-ready. The silencing inserts obtained from the 2 annealled RNAi oligos (Methods 2.2.5.3.2.1) were diluted to a final concentration of 8ng/μl with nuclease-free water. Four 10μl ligation reactions (three with the annealed siRNA inserts, one with the annealing solution as negative control) were set up as follows: 
Reaction 1	Reaction 2	Reaction 3	Negative control reaction
1µl diluted annealed siRNA insert 1	1µl diluted annealed siRNA insert 2	1µl diluted annealed s4iRNA insert 3	1µl 1×DNA annealing solution
1μl pSilencerTM 4.1-CMV neo vector
1μl T4 DNA ligase
1μl 10 × T4 DNA Ligase Buffer
6μl nuclease-free water





Three microlitres of each ligated plasmid was added to 200μl of competent DH5α cells and incubated on ice for 30 min. A falcon tube containing only DH5α competent cells was used as a negative control. All reactions were transferred into 42℃ water bath for exact 90 sec, and placed on ice for 2 min. Eight hundred microlitre of freshly made SOC medium was preheated to 42℃ and added to each reaction then incubated at 37 ℃ for an hour with shaking at 225 rpm. The transformation reaction was then plated onto LB-amp agar plates each containing 100μg/ml ampicillin and incubated overnight at 37℃. Following incubation, colonies were picked and grown in10ml LB amp medium each at 37℃ with shaking at 225 rpm overnight. Plasmids were then extracted using the Qiagen Plasmid mini-preparation kit (see below). Plasmid midi-preparation could also be performed when transferring 1ml of the overnight 10ml culture into 100ml LB-amp medium and grow for another 4 hours at 37℃ with shaking at 225 rpm. To ensure the optimal plasmid extraction, cell growth should be stopped when OD550 reached 1-1.3.

2.2.5.3.2.5	Mini and midi preparation of plasmid DNA





Five millimitres of overnight culture was pelleted by centrifugation at 6000g for 15 min at 4℃ and the supernatant was discarded. The pellets were collected and transferred to a 1.5 ml microfuge tube and resuspended in 250μl of Buffer P1. Buffer P2 (250μl) was then added and mixed by gently inverting 4-6 times. The mixture was incubated at room temperature for 5 min. Chilled Buffer N3 (350μl) was added and mixed immediately and thoroughly by inverting 4-6 times. At this point the solution becomes cloudy in colour. This was then centrifuged at 13,000rpm for 10 min and the supernatant containing plasmid DNA was applied to a miniprep column Qiagen-tip 20. It was centrifuged at maximum speed for 1 min and the flow through was discarded. The column was washed by adding 750µl Buffer PE and centrifuged for 1 min again. The flow-through was also discarded and the column was centrifuged again for an additional 1 min to remove residual wash buffer. The column was put in a clean 1.5ml microfuge tube and 50µl Buffer EB was added and allowed to stand for 1 min. DNA was eluted by centrifuging for 1min at 13,000rpm. 

2.2.5.3.2.5.2	Midiprep DNA extraction
Approximately 100-200mls of bacterial cell culture was harvested by centrifugation at 6000g for 15 min at 4℃ and the pellet resuspended in 4ml of Buffer P1 followed by 4ml Buffer P2, mixed by inverting 4-6 times and incubated at room temperature for 5 min. After incubation, 4ml of chilled Buffer P3 was added, mixed immediately by inverting 4-6 times and incubated on ice for 15 min before centrifugation at maximum speed for 30 min at 4 ℃. Meanwhile, the midiprep column Qiagen-tip 100 was equilibrated by applying 4ml Buffer QBT and allowed to flow through under gravity. The supernatant containing DNA from the previous centrifugation was applied to the equilibrated column and allowed to enter the resin by gravity flow. The column was then washed twice with 10 ml Buffer QC. The DNA was eluted from the resin with 5 ml of Buffer QF and precipitated with 3.5 ml isopropanol. The mixture was then centrifuged at maximum speed for 30 min at 4℃ and the pellet resuspended in 2ml of 70% ethanol and centrifuged at maximum speed for a further 10 min. The supernatant was decanted carefully so as not to disrupt the pellet which was then air-dried for 5-10 min. The DNA was dissolved in 50μl TE buffer (pH8.0). Extracted DNA was stored at -20 ℃.

2.2.5.3.2.6	Double digestion of DNA products









The sequence analysis was conducted by using the internal pSilencer 4.1-CMV neo sequence primer to sequence the cloning site of the plasmid. Plasmid DNAs were sent for sequencing to Cogenics Lark Inc. The results were analysed using BIOEDIT sequence visualisation software.

2.2.5.3.3	Transient and stable transfection

Ambion’s siPORT XP-1 transfection agent was used to perform both the transient transfection and the stable transfection. 




After the most appropriate incubation time, RSM containing 0.1% G418 was used to replace the RM. RSM was changed every three days for both parental and transfectant cells. Geneticin (G418 sulphate) is a selective antibiotic which blocks polypeptide synthesis by inhibiting protein elongation; resistance is conferred by the presence of a resistant gene in the transfection vector. Thus unsuccessfully transfected cells were killed by G418; and the successfully transfected cells were survived in the RSM.

2.2.5.3.5	Ring cloning of transfected cells

The transfected cells were distributed into several bigger dishes at a low density so that each cell can grow and form an individual colony.






Growth of cells in soft agar is one of the hall mark characteristics of cellular transformation and uncontrolled cell growth. The more malignant a tumour cell, the greater the ability to form colonies of cells. Soft agar assay was performed to test the tumorgenecity or the ability for cells to form tumours in vitro. In this experiment, parental cells and the siRNA transfectant cells were cultured in soft agar to determine their ability to form colonies.












Each cell line was harvested and counted with a haemocytometer, and adjusted to a density of 1×104 cells/ml. Two hundred microlitres of each cell line was plated in triplicate in a 96-well plate to make 2×103 cells/well. The proliferation assay was run for 6 days, so 6×96-well plates were seeded to enable measurements on each experimental day. All plates were incubated at 37℃ and 5% CO2.

2.2.6.2.3	Determination of cell numbers by MTT

MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide, a tetrazole) is a chemical which can enter into the mitochondrion of the cell. It is converted by oxidative enzymes into a soluble blue dye known as formazan which forms blue crystals in the cell cytoplasm. Addition of DMSO causes the Formazan crystal to dissolve and the depth of the blue solution obtained is directly proportional to the number of cells present. Optical density of the dye will be measured at 595nm. A standard curve can be established by plotting OD against cell density. The experimental cell density would then be determined through the standard curve.




Invasiveness is a very important feature, distinguishing benign from malignant lesions. Tumour cells, when establishing colonies at secondary sites, must move through tissue boundaries that normal cells do not cross. Invasiveness and motility are indicative of tumor malignancy. 
An invasion assay was performed to test the invasiveness of cells as follow:








This assay was performed to investigate the effect of silencing S100A4 or OPN in tumorgenecity in vivo. 

2.2.7.1	Mice and cell lines

All animal work was conducted according to UKCCCR guidelines under Home Office project licence PPL40/2270 to Prof Y Ke and the personal licence (PIL40/8714) to Y Zhang. 
Six to eight week-old male Balb/c nude mice were purchased from Charles River Laboratories. Their body weights were measured on arrival and ranged from 18-20g. The mice were divided into five groups (eight per group) and maintained in a single room equipped to the required environment in the University Biomedical Service building. 
The following five cell lines were tested in the five groups of mice at the same time:
Group 1: control cells
Group 2: OPN-moderately-suppressed transfectant ODC4
Group 3: OPN-highly-suppressed transfectant ODC10
Group 4: S100A4-highly-suppressed transfectant SDC2




After a week of quarantine, each mouse was inoculated with a single subcutaneous injection of cells. 
On the day of the inoculation, all cells (control cells, ODC10, ODC4, SDC2, and SDC11) were harvested and counted. Cells were washed with PBS twice to remove serum and then resuspended in PBS at a concentration of 2×107 cells/ml. An equal volume of thawed Matrigel was added to the cells and mixed well. The cell suspensions were kept on ice to prevent gelling. Each mouse was given a subcutaneous injection on the right shoulder region of 200ul suspension containing 2×106 cells for each cell line. Tumours appeared approximtely a week after inoculation. Body weight and the tumor size were measured twice a week using a calliper. Tumor volume was calculated by the formula 0.5236× (length) ×(width) × (height) 246. The animals were followed for 4 weeks, or until the tumours reached 17mm in one dimension, when the mice were sacrificed. At autopsy, dissections were performed to remove primary tumor tissue (where available), lungs, liver, kidneys and pancreas and these were placed in 10% formalin tissue fixation. At autopsy, primary tumours were divided to three pieces, one was fixed in 10% formalin, and one was snap frozen to the liquid nitrogen for protein and RNA testing. Another piece was kept in PBS and used for primary culture. 

2.2.7.3	Processing of tumor and tissue from mice

The primary tumor tissue and other body tissues from sacrificed mice were fixed in 10% formalin for at least 24 hours. The fixed tissues were trimmed and placed within embedding cassettes and processed on a Shandon processor. The tissues were then washed for 1 hour in 70% ethanol, 1 hour in 90% ethanol, 4×1 hour in absolute ethanol, 3×1 hour in xylene and 2×1.5 hour in paraffin wax 60oC and then, the processed tissues were embedded in paraffin wax and cooled on ice. Paraffin embedded tissues were cut into 4μm sections as described in Methods 2.2.4.2.2 and stained for the detection of OPN and S100A4 as described in Methods 2.2.4.3.

2.2.7.4	Detection of OPN and S100A4 protein in mice tissues

Detection of OPN and S100A4 was performed on tumor and other tissue sections using the same methodology as described in Methods 2.2.4.3. Primary anti-OPN and anti-S100A4 antibodies were used at a dilution of 1:250 and 1:500 respectively.

2.2.7.5	Extraction of protein from the tissue and Western Blot analysis

The snap frozen tumor tissues were defrost on ice for 1 hour and tissues were cut into small pieces and put in the microfuge tubes filled with 500µl Cellytic-M. The tissues in each tube were sonicated at 4×10 sec in 100% power (Bandelin, Berlin). During this procedure, samples were kept on ice to avoid damaging protein with high temperature. After sonication, samples were centrifuged at the max speed for 30 min and the supernatant containing the protein was transferred to a new microfuge tube and proteinase inhibitor was added to each protein at 10μl/ml. The pellets of the tissues were kept in the -80℃. Western blotting was performed to test the OPN and S100A4 protein expression as described in Methods 2.2 3.

2.2.7.6	Primary tumor cell culture























Chi-Square was used to compare the difference shown in the immunohistochemical staining between the normal, BPH and carcinoma samples and also the carcinoma samples with different GS, GS<5, GS6-7, GS8-10 samples. For all calculations, a value of p<0.05 was used to define the statistical significance.

2.2.8.4	Two-sided Fisher’s exact test




























CHAPTER THREE: Result 1- Anterior gradient-2 (AGR2)

3.1.	AGR2 expression in prostate cell lines

Western blot analysis detected a single AGR2 band with a size of 20kD in the benign PNT2 cell line and in highly malignant cell lines, PC3 and PC3M (Fig 3.1A). The detailed quantitative measurements of relative AGR2 levels expressed in different cell lines were shown in Fig 3.1B. When the level of AGR2 expressed in the PNT2 cells was set at 1.0, the relative levels of AGR2 in the malignant cell lines PC3 and PC3M were 5.29±0.14 and 3.81±0.23, respectively. No AGR2 protein was detected in the weakly malignant cell line LNCaP and highly malignant DU145.

3.2.	AGR2 expression in prostate tissues

Examples of immunohistochemical stains of different prostate tissues with rabbit polyclonal anti-human AGR2 antibody were shown in Fig 3.2. In normal prostate gland as shown in Fig 3.2A, AGR2 staining was localized predominantly to the cytoplasm of luminal cells of prostate glands, whereas in the prostate carcinomas (Fig 3.2C-E), both cytoplasmic and nuclear stains were observed. It showed the negative or weakly staining in normal prostate (Fig 3.2A) and BPH (Fig 3.2B). As represented in Fig 3.2C-E, it stained from moderately to strongly with the increasing malignancy of the carcinoma tissues. And in Fig 3.2F, a strongly stain was observed in a malignant carcinoma (large arrow) while it was negative in the adjacent benign areas (small arrow) within the same tissue sample. When the antibody was neutralized with the recombinant AGR2 protein, the stain was completely blocked (Fig 3.2G and H), indicating the specificity of the antibody for AGR2. 
Amongst seven normal prostate tissues, one (14.3%) was unstained, five (71.4%) stained weakly and one (14.3%) stained moderately positive. Amongst 34 BPH cases, 12 (35.3%) were unstained, 18 (52.9%) stained weakly positive and four (11.8%) stained moderately positive (Table 3.1). The difference of AGR2 stains between normal and BPH cases was not statistically significant (Chi-square test, p=1.19). Amongst 65 carcinoma cases, three (4.6%) were unstained, 14 (21.5%) stained weakly positive, 19 (29.2%) stained moderately positive, and 29 (44.9%) stained strongly positive (Table3.1). The staining in carcinoma cases for AGR2 was significantly higher than those observed in normal (Chi-square test, p<0.02) and BPH (Chi-square test, p<0.0001) cases. These 65 carcinoma cases were divided into three categories according to the malignancy which was represented by Combined Gleason Scores: GS≤5, GS6-7, and GS8-10 (Table 3.1). 
Table 3.1 AGR2 expression in different prostate tissues
Tissues	AGR2 expression	No. of cases








3.3.	Correlation with patient survival

3.3.1.	AGR2 expression and patient survival

The relationship between the strength of AGR2 staining and the patient-survival time was shown in Fig 3.3A. For patients with strongly positive AGR2 stains, the median survival time was 36.3 months, which was significantly shorter than 75 months and 80 months for patients with moderately (log rank test, p=0.03) and weakly (log rank test, p=0.006) positive AGR2 stains, respectively. Overall survival time was significantly (log rank test, p=0.007) reduced with increased AGR2 stains. The difference in median survival time between moderately and weakly positive AGR2 staining groups was not significant (log rank test, p=0.25).

3.3.2.	Combined Gleason Scores (GS) and patient survival

To assess the relationship between the GS and patient survival, 65 carcinoma cases were divided into the weakly malignant group with GS of ≤5, the moderately malignant group with GS of 6-7 and the highly malignant group with GS of 8-10. The median survival time of patients with weakly, moderately and highly malignant carcinomas was 80, 48 and 24 months, respectively (Fig 3.3B). The reduced survival time was significantly (log rank test, p=0.002) associated with the increased degree of malignancy.

3.3.3.	Prostate-Specific Antigen (PSA) and patient survival

The correlation between PSA level and patient-survival time was shown in Fig 3.3C. The median survival time for patients with low (<4ng/ml) and borderline (4-10ng/ml) PSA level was 60.9 months compared with 48.3 months in patients with high (>10ng/ml) PSA levels. Although survival time has been reduced in patients with high PSA level, the association of the patient PSA level with the length of the survival time was not significant (log rank test, p=0.108).

3.3.4.	Androgen receptor (AR) and patient survival

The correlation between AR and survival time was shown in Fig 3.3D. The median survival time for patients with low (index<4) and high (index≥4) AR levels was 60.6 and 48 months, respectively. The time of patient survival and the level of AR were not significantly (log rank test, p=0.485) associated.

3.4.	Correlation between differently selected variables expressed in prostate cancer

3.4.1.	AGR2 expression and Combined Gleason Scores (GS)

Amongst 15 GS≤5 carcinomas, 13 (86.6%) stained weakly positive and two (13.3%) stained moderately positive. Amongst 26 GS6-7 carcinomas, two (7.7%) were unstained, 15 (57.6%) stained moderately positive and nine (34.6%) stained strongly positive. Amongst 24 GS 8-10 carcinomas, one (4.1%) was unstained, one (4.1%) stained weakly positive, two (8.3%) stained moderately positive and 20 (83.3%) stained strongly positive (Table 3.1). The strengthened AGR2 staining was significantly (Chi-square test, p<0.0001) associated with the increased GS of the carcinomas.

3.4.2.	AGR2 expression and Prostate-Specific Antigen (PSA) level

The correlation between levels of PSA and AGR2 expression was shown in Fig 3.4A. For patients with weak, moderate and strong AGR2 stains, the median PSA level was 6.85, 6.20 and 10.3ng/ml, respectively. Box plot analysis showed that the level of PSA in the patients with strong AGR2 staining was significantly higher than that of patients with moderate (Mann-Whitney U test, p=0.015) and weak (Mann-Whitney U test, p=0.007) staining. However, the difference in patient PSA levels between moderate and weak AGR2 stained groups was not significant (Mann-Whitney U test, p=0.095).

3.4.3.	AGR2 expression and Androgen receptor (AR) index

The correlation of AR index with AGR2 expression was shown in Fig 3.4B. For patients with weak AGR2 stains, the median AR index was 1. For patients with moderate and strong AGR2 stains, the median AR indexes were 4. Box plot analysis showed that the difference in patient AR indexes either between strong and moderate AGR2 stained groups (Mann-Whitney U test, p=0.600), or between strong and weakly stained groups (Mann-Whitney U test, p=0.286), was not significant.

3.4.4.	Prostate-Specific Antigen (PSA) and Combined Gleason Scores (GS)





The aim of this chapter was to establish whether or not AGR2 could be the prognostic biomarker for prostate cancer. The work represented the expression status of AGR2 in prostate cancer cells and tissues. The positive outcomes were associated with the patient data, especially the patient survival time.
AGR2 was originally found in human breast cancer. Using suppression subtractive hybridization, it was found that 29 genes expressed in Estrogen receptor (ER)-positive breast carcinomas might contribute to its less aggressive phenotype when compared to ER-negative tumor. The ER expression in 8 breast carcinoma cell lines was correlated with the expression of one of the 29 genes, DEME2247. After screening an ER-positive breast cancer cell cDNA library with the DEME2 probe and searching EST database, AGR2, human homologue of the Xenopus laevis cement gland anterior gradient (XAG-2) protein was discovered41. It was found that XAG-2 was a direct inducer of anterior neural fate of Xenopus ectoderm and its overexpression did not result in activation of cephalic hedgehog nor in induction of noggin expression37. The deduced 175-amino acid soluble AGR2 protein, which is 91% and 47% identical to mouse and frog homologues, respectively, contains a signal peptide. Northern blot analysis detected AGR2 transcripts of 0.9- kb in lung cancer cells and 1.6-kb in ER-positive breast cancer cells; whereas a weaker expression was detected in pancreas. RNA dot blot analysis detected a strong AGR2 expression in trachea, lung, stomach, colon, prostate, and small intestine41. By immunohistochemistry and real-time quantitative PCR analyses, it was found that AGR2 mRNA and protein exhibited similar increase in breast cancer tissues and expression of AGR2 was correlated with expression of estrogen receptor248. In a recent study, it was found that there was a significantly progressive reduction in patient survival time with increasing AGR2 staining solely in ER-positive cases39. Further analysis suggested that AGR2 was a prognostic marker in breast cancer for the subgroups of nodal negative stage I tumors249. Recently, preliminary investigations were performed on the possible role of AGR2 in other diseases, such as inflammatory bowel disease250 and prostate cancer47, 251. Although it was reported that overexpression of AGR2 was detected in prostate cell lines and carcinomas; its actual role in malignant progression was not clear. Its prognostic significance in patient survival has not been previously investigated.
We first examined the AGR2 expression status in five commonly used prostate cell lines (Fig 3.1). We found that two of the four (50%) malignant cell lines expressed 3.8 to 5.3 times more AGR2 than the benign PNT2 cells, whereas another two malignant cell lines did not express AGR2. This result showed that the elevated expression of AGR2 is associated with increased malignant characteristics in 50% of the cell lines examined, indicating that it is possible that the increased AGR2 expression plays a promoting role in the development and metastasis of prostate cancer cases.252, 253
The immunohistochemical analyses (Table 3.1) showed no significant (Chi-square test, p=1.19) difference in AGR2 staining strength between normal (Chi-square test, p<0.02) and BPH (Chi-square test, p<0.0001) cases. However, significant increase in AGR2 level was observed in carcinomas compared to normal and BPH cases. Furthermore, AGR2 staining was significantly stronger (Chi-square test, p<0.0001) in moderately malignant tissues than that in weakly malignant tissues. Similarly, highly malignant carcinomas exhibited significantly stronger AGR2 stains than weakly (Chi-square, p<0.0001) and moderately (Chi-square, p<0.01) malignant carcinomas. These results suggest that, increased AGR2 expression was significantly associated with increased malignant changes as reflected by the increased GS. Thus increased AGR2 expression may be an indicator for the malignant progression of prostate cancer. 
The overall increment of AGR2 expression was significantly (log Rank test, p=0.007) associated with the reduced time of patient survival. The survival time of the patients with strong AGR2 staining was significantly shorter than that of the patients with moderate and weak AGR2 staining (Fig 3.3A). This result showed that the overall increased AGR2 expression was significantly associated with the poor prognosis in terms of patient survival. Further assessment showed that the patient survival time (Fig 3.3B) was significantly (log Rank test, p=0.002) correlated in a reciprocal manner to the degree of malignancy classified by GS. These results suggested that like GS of the carcinomas, the AGR2 staining strength was also a very useful parameter in predicting patient outcome.  
PSA is currently the most widely used marker for prostate cancer254, 255. In this study, although the survival time was reduced with increased PSA level (Fig 3.3C), the increased PSA level was not significantly (log Rank test, p=0.108) associated with the reduced patient survival time. Thus, in this group of patients studied, PSA level was not a reliable prognostic marker. AR was believed to play an important role in regulation of the malignant progression of prostate cancer256, 257, but the result (Fig 3.3D) in this study showed there was no significant (log Rank test, p=0.485) association between AR index and the time of patient survival.
When the correlations between AGR2 expression and PSA level (Fig 3.4A) and between AGR2 and AR index (Fig 3.4B) were assessed, the level of PSA in the patients with strong AGR2 staining was significantly higher than that of the patients with moderate staining (Mann-Whitney U test, p=0.007) and weak staining (Mann-Whitney U test, p=0.015), but the difference in patient PSA levels between moderate and weak AGR2 stains was not significant (Mann-Whitney U test, p=0.095), suggesting that the level of AGR2 expression was partially associated with the level of PSA. In contrast, the difference in patient AR indexes was neither significant between strong and moderate AGR2 stained cases (Mann-Whitney U test, p=0.600), nor between strong and weakly stained cases (Mann-Whitney U test, p=0.286). These results suggest that the expression of AGR2 was not related to that of AR in the cases of prostate cancer studied in this work, although AGR2 was closely related to Estrogen Receptors (ER) in breast cancer48. More study is required to find out why AGR2 acts in such a different manner in breast and prostate cancers.  
The assessment (Fig 4.4C) showed that PSA level was significantly higher in patients with highly malignant carcinomas than those with weakly (Mann-Whitney U Test, p=0.001) and moderately (Mann-Whitney U Test, p=0.02) malignant carcinomas, whereas the difference between the moderately and weakly malignant carcinoma cases was not significant (Mann-Whitney U Test, p=0.308). This result showed that although PSA is not suitable to be a prognostic marker, it can partially reflect the degree of malignancy of the carcinomas in these groups of patients. 
In conclusion, AGR2 was expressed in higher levels in some malignant prostate cell lines and tissues compared with the normal and BPH cases. The increased AGR2 expression was significantly associated with the increased malignancy of the carcinoma and the reduced survival time of patients. Therefore, the increased expression of AGR2 may be a valuable prognostic marker to predict the outcome of patients with prostate cancer. 










































CHAPTER FOUR: Result 2 - S100A4

4.1.	S100A4 expression in prostate cell lines

A strong S100A4 protein band at 10kD was detected by Western blot in highly malignant cell line DU145 and a weaker band on the same position was detected in the highly malignant cell lines PC3 and PC3M while no band was detected in the benign cell line PNT2 and the weakly malignant cell line LNCaP, as shown in Fig 4.1A. The detailed quantitative measurements of relative S100A4 levels expressed in different cell lines were shown in Fig 4.1B. When the level of S100A4 expressed in the PC3M cells was set at 1.0, the relative levels of S100A4 in DU145 and PC3 were 23.2±0.2 and 2.7±0.1, respectively.

4.2.	S100A4 expression in prostate tissues

The representative samples of immunohistochemical stains of different prostate tissues with the polyclonal anti-human S100A4 antibody were shown in Fig 4.2. No staining was observed in the normal prostate tissues as shown in Fig 4.2A. In benign prostate tissues, S100A4 staining was localized in stroma, not in glandular cells (Fig 4.2B). Weakly positive staining (Fig 4.2C)and strongly positive staining (Fig 4.2F) was shown in both stroma and glandular cells in weakly malignant tissues and highly malignant tissues respectively while some of the moderately malignant tissues were stained strongly positive (Fig 4.2D) and some were unstained (Fig 4.2E). The stain was completely blocked when the antibody was neutralized with the recombinant S100A4 protein (Fig 4.2G and H), indicating the specificity of the antibody for S100A4. 
The results of immunohistochemical staining were summarized in Table 4.1.
Amongst 7 normal prostate tissues, 6 (86%) was unstained, 1 (14%) stained in stroma. Amongst 34 BPH cases, 30 (88%) were unstained, 4 (12%) stained in stroma (Table 4.1). The difference of S100A4 stains between normal and BPH cases was not statistically significant (two-sided Fisher’s exact test, p>1). Amongst 110 carcinoma cases, 44 (41%) were unstained, 66 (59%) stained (Table4.1). Expression of S100A4 in carcinoma cases was significantly higher than that in benign (two-sided Fisher’s exact test, p<0.0001) and normal (two-sided Fisher’s exact test, p<0.05). 
Table 4.1 S100A4 expression in different prostate tissues
Tissues	Stain  Intensities (Stroma)	No. of cases
	Negative(-)No. (%)	Positive(+)No. (%)	







4.3.	Correlation with patient survival

4.3.1.	S100A4 expression and patient survival

The relationship between the intensity of S100A4 staining and the patient-survival time was shown in Fig 4.3A. For the patients with positive S100A4 stains, the median survival time was 48 months. For the patients with negative S100A4 stains, the median survival time was 60 months. Although there is some difference between the median survival time, statistic analysis showed that the survival time was not significantly (log rank test, p=0.77) reduced with increased S100A4 stains.

4.3.2.	Combined Gleason Scores (GS) and patient survival

To assess the relationship between the GS and patient survival, 110 carcinoma cases were divided into the weakly malignant group with GS of <6, the moderately malignant group with GS of 6-7 and the highly malignant group with GS of 8-10. The median survival time of patients with weakly, moderately and highly malignant carcinomas was 85, 60 and 24 months, respectively (Fig 4.3B). The reduced survival time was significantly (log rank test, p<0.001) associated with the increased degree of malignancy.

4.3.3.	Prostate-Specific Antigen (PSA) and patient survival

The correlation between PSA level and patient-survival time was shown in Fig 4.3C. The median survival time for patients with low (<4ng/ml) and borderline (4-10ng/ml) PSA level was 72 months compared with 48 months in patients with high (>10ng/ml) PSA levels. The association of the patient PSA level with the length of the survival time was significant (log rank test, p<0.05).

4.3.4.	Androgen receptor (AR) and patient survival

The correlation between AR and survival time was shown in Fig 4.3D. The median survival time for patients with low (index<4) and high (index≥4) AR levels was 61.4 and 61.9 months, respectively. The time of patient survival and the level of AR were not significantly (log rank test, p=0.151) associated.

4.4.	Correlation between differently selected variables

4.4.1.	S100A4 expression and Combined Gleason Scores (GS)

Amongst 21 GS≤5 carcinomas, 13 (61.9%) stained negative and 8 (38.1%) stained positive. Amongst 46 GS6-7 carcinomas, 20 (43.5%) were unstained, 26 (56.5%) stained positive. Amongst 43 GS 8-10 carcinomas, 11 (25.6%) was unstained, 32 (74.4%) stained positive (Table 3.1). The intensity of S100A4 staining was significantly (Chi-square test, p<0.02) associated with the increased GS of the carcinomas. 

4.4.2.	S100A4 expression and Prostate-Specific Antigen (PSA) level

The correlation between levels of PSA and S100A4 expression was shown in Fig 4.4A. For patients with negative and positiveS100A4 stains, the median PSA level was 20.0 and 37.1ng/ml, respectively. Though there was 17.1ng/ml difference between the median, box plot analysis showed that the level of PSA in the patients with positive S100A4 staining was not significantly (Mann-Whitney U test, p=0.614) higher than that of patients with negative staining. 

4.4.3.	S100A4 expression and Androgen receptor (AR) index

The correlation of AR index with S100A4 expression was shown in Fig 4.4B. For patients with negative S100A4 stains, the median AR index was 3.9. For patients with positive S100A4 stains, the median AR indexes were 3.5. Box plot analysis showed that the difference in patient AR indexes between negative and positive S100A4 stained groups was not significant (Mann-Whitney U test, p=0.597).

4.4.4.	Prostate-Specific Antigen (PSA) and Combined Gleason Scores (GS)

The correlation of PSA levels and GS was shown in Fig 4.4C. For patients with GS≤5, GS6-7 and GS 8-10 carcinomas, the median PSA levels were 15.9, 24.9 and 39.0ng/ml, respectively. Box plot analysis showed that the PSA level was significantly higher in patients with GS 8-10 carcinomas than those with GS≤5 (Mann-Whitney U test, p=0.024) and GS 6-7 carcinomas (Mann-Whitney U test, p=0.027). However, the difference in patient PSA levels between the GS 6-7 and GS≤5 carcinoma groups was not significant (Mann-Whitney U test, p=0.911).

4.5.	RNA interference stably decreased S100A4 expression

DU145 prostate cells are highly malignant and expressing high level of S100A4 as shown in Fig 4.1. RNAi was used to suppress S100A4 in DU145 cells specifically.

4.5.1.	Selection of efficient siRNA for S100A4 suppression

Three 21-nt sequences within the S100A4 cDNA for RNAi were selected and used to make double-stranded 21-nt siRNA constructs encoding sense and antisense siRNA. These three siRNAs were transient transfected to the DU145 cell line both separately and in differently combined manners as described in Methods. After 72 hours, the transient transfectants were subjected to Western blot analysis for their S100A4 expression level. SiRNA11 exhibited the highest efficiency in suppressing S100A4 expression. It reduced the S100A4 expression by nearly 5 fold from the level detected in parental DU145 cells (Fig 4.5.1). Thus, siRNA11 was identified as the best siRNA used for further study.

4.5.2.	Establishment of S100A4 stably suppressed clones

The plasmid express siRNA11 against S100A4-cDNA target was designed and constructed as described in Methods. Sense and antisense siRNA sequences were arranged sequentially to facilitate the formation of hairpin siRNA upon transcription. DU145 cells were transfected with purified pSilencerTM 4.1-CMV neo vector containing either the siRNA11 insert or the scrambled siRNA control insert. pSilencerTM 4.1-CMV neo vector contains a neomycin resistance gene. The selection medium (RSM) containing 1mg/ml neomycin G418 was applied 24 hrs after transfection. Three months after the initial transfection, several clones in which the S100A4 expression was suppressed were established. They were named S100A4-suppressed-DU145-clone (SDC) 1, SDC2, SDC3…etc, respectively. Western blot was performed to detect their S100A4 expression as shown in Fig 4.5.2. Result showed that the level of S100A4 in clone SDC11 and SDC2 had been moderately and highly suppressed by 4 and 28 folds, respectively, compared with sR-control transfectant. Thus, S100A4-moderately-suppressed clone SDC11 and S100A4-highly-suppressed clone SDC2 were chosen to do the further investigation. 

4.6.	Effect of suppression of S100A4 on tumor cells in vitro

4.6.1.	Suppression of S100A4 significantly inhibited anchorage-independent growth of cancer cells

The soft agar colony-formation assay was performed to investigate the effect of S100A4 suppression on anchorage-independent growth of DU145 cells. As shown in Fig 4.6.1, no significant differences (student’s t test, p=0.82) were observed between the number of colonies formed by the parental DU145 cells and the scrambled-RNA transferctant (sR-control). Numbers of colonies produced in soft agar by S100A4-highly-suppressed cells SDC2 (student’s t test, p<0.0001) and S100A4-moderately-suppressed cells SDC11 (student’s t test, p<0.001) significantly reduced by 11.4 and 3.5 folds, respectively, in comparison with sR-control. 

4.6.2.	Suppression of S100A4 had no effect on cellular proliferation

Cell proliferation assay was performed in 120 h to measure the growth rate for SDC clones. The density of the cultured cells was determined by extrapolating from the standard curve and cell numbers were obtained by MTT assays as described in Methods. Cell proliferation rates of SDC2 (student’s t test, p=0.984) and SDC11 (student’s t test, p=0.359) did not show any significant difference from the sR-control cells.

4.6.3.	Suppression of S100A4 significantly inhibited the invasiveness of the cancer cells

The invasiveness of SDC clones were assessed using Matrigel coated transwell invasion chambers as described in Methods. The parental DU145 cells and the sR were used as controls. While no significant (student’s t test, p=0.47) difference between parental DU145 cells and sR-control cells was observed, the invasiveness of SDC2 (student’s t test, p<0.0001) and SDC11 (student’s t test, p<0.003) was reduced by 4.9 and 1.6 fold respectively, in comparison with sR-control (Fig 4.6.3B). Fig 4.6.3A represented the proportion of cells invaded into Matrigel in DU145, sR-control, SDC2 and SDC11.

4.6.4.	Suppression of S100A4 had no effect on cellular motility





The aim of this chapter was to establish whether or not S100A4 could be the prognostic biomarker for prostate cancer and if it plays a role in the malignancy of prostate cancer. Expression of S100A4 in prostate cell line and tissues were investigated in this work and the expression status of this protein was correlated with the patient survival data. The expression of S100A4 was knocked down in the malignant prostate cancer cell line and the role of S100A4 in the malignancy was assessed in vitro.
S100A4 was first identified in 1987 by Jackson-Grusby75. An mRNA was characterized after serum stimulation of quiescent mouse fibroblasts and this mRNA, designated 18A2 was found encoding a predicted polypeptide of 101 amino acids with homology to known calcium binding proteins75. S100A4 mRNA expression level was found to be related to the metastatic phenotype in several tumor cells73. The role of S100A4 in metastasis was then studied in a variety of cancers115, 261, 262, mouse models263 264 and even related to tumor suppressor p53123. After these extensive investigations, S100A4 was widely accepted as a metastasis-inducing protein. 
In contrast to the rapid progress of the study on the role of S100A4 in metastasis, its role in prognosis of cancer was not studied until 2000. Studies on patients with19 years follow-up survival data in stage I and II breast cancer suggested that the length of median survival time between S100A4-negative group (>228 months) and S100A4-positive group (47 months)134 was significantly different. The result of another study of 10- year follow-up survival data in early stage also supported that S100A4 could be a valuable marker of prognosis for breast cancer265. However, the controversial results were presented in 2002 by Pedersen. 66 breast carcinoma samples of I-IV stages on a were with 79 months follow-up time were studied and the S100A4 immunoreactivity was not associated with overall survival, although high expression of S100A4 did relate to the histological grade III and had a inverse correlation with the expression of estrogen receptor103. This contrast result may be explained by the small sample volume and the short follow-up time and other technique conditions. Thus, the prognosis of S100A4 in breast cancer is still widely accepted. The prognostic significance of S100A4 has recently been evaluated in a series of cancers, a worse prognosis for patients was correlated with the increase S100A4 expression in colorectal136, gallbladder106, bladder138, esophagel107, non-small-cell lung109, gastric140, medulloblastoma85, pancreatic142 and hepatocellular143 cancers. 
S100A4 was first studied in the Dunning R3327 rat prostate cancer model in 1997. Western blot and Northern blot were applied to analyze S100A4 at both protein and mRNA levels in different metastatic prostate cancer cell lines and the association between elevated expression of S100A4 and increased metastatic capability was revealed.131 Association between the increased S100A4 expression with the increased prostate cancer progression was first discovered by using RT-PCR, Western blot and immunohistochemistry techniques on normal, BPH and carcinoma samples.105  S100A4 expression was detected in transgenic adenocarcinoma of the mouse prostate (TRAMP) model during autochthonous prostate cancer progression. Inhibition of prostate cancer expression by feeding GTP on TRAMP mice was associated with reduction of S100A4 and restoration of E-Cadherin.132 
In this study, the expression status of S100A4 was first examined in the five commonly used prostate cell lines (Fig 4.1). All highly malignant cell lines, DU145, PC3 and PC3M were found expressed S100A4 whereas it was expressed in neither of the benign cell line PNT2 nor the weakly malignant cell line LNCaP. Amongst three highly malignant cell lines, highest level of S100A4 expression was found in DU145 which was 23.2 fold than that of PC3M and PC3 expressed S100A4 at 2.7 fold compared to that of PC3M. Thus, in prostate cell lines, the high expression of S100A4 appeared to be closely linked to the high malignant potential of the cells. Increased S100A4 may involve in the malignancy progression of cancer cells in prostate.
The immunohistochemical staining of S100A4 may be divided into two parts: stains in glandular cells and stains in stroma (Fig 4.2). In normal tissues, no stain was observed in glandular cells or stroma. In BPH, only stroma was stained; in carcinomas, both stroma and glandular cells were stained but in different intensities. The immunohistochemical analyses (Table 4.1) showed no significant (two-sided Fisher’s exact test, p>1) difference in S100A4 stain intensities between normal and BPH cases. However, significant increase in S100A4 expression was observed in carcinomas compared to normal (two-sided Fisher’s exact test, p<0.05) and BPH (two-sided Fisher’s exact test, p<0.0001) cases. Furthermore, S100A4 staining was significantly stronger (two-sided Fisher’s exact test, p<0.01) in highly malignant tissues (GS8-10) than that in weakly malignant tissues (GS<6). This result suggested that increased S100A4 expression may be an indicator for the malignant progression of prostate cancer. 
Although the median survival time for patients with positive (48 months) S100A4 stains was 12 months shorter than those stained negatively (60 months) (Fig 4.3A), this difference was not statistically significant (log rank test, p=0.77). This result suggested the S100A4 stain intensity increment may not be used to accurately predict the patient outcome. However, the reduced patient survival time (Fig 4.3B) was shown to be significantly (log rank test, p<0.001) associated with the increased GS which measured the degree of malignancy in prostate cancer. This result as reported consistently by our group that GS of the carcinomas was a useful prognostic parameter for outcomes of patients38.
In present work, as shown in Fig 4.3C, the increased PSA level was not significantly (log Rank test, p<0.05) associated with the reduced patient survival time. However, it showed there was no significant (log Rank test, p=0.151) association between AR index and the time of patient survival (Fig 4.3D).
The level of PSA in patients with positive S100A4 stains was not significantly (Mann-Whitney U test, p=0.614) higher than that of patients with negative stains, although there was difference of 17.1ng/ml between the median PSA level of these two groups. This result suggested that the increased level of S100A4 expression was not significantly associated with the increased level of PSA. Similarly, the difference in patient AR indexes was not significant (Mann-Whitney U test, p=0.597) between positive and negative S100A4 stained cases, indicating that the expression of S100A4 was not related to the AR index in the cases of prostate cancer studied in this work. This result is in contrast to that with the ER in breast cancer, which was closely related to S100A448. 
The assessment (Fig 4.4C) showed that PSA level was significantly higher in patients with highly malignant carcinomas than those with weakly (Mann-Whitney U Test, p=0.024) and moderately (Mann-Whitney U Test, p=0.027) malignant carcinomas, whereas the difference between the moderately and weakly malignant carcinoma cases was not significant (Mann-Whitney U Test, p=0.911). This result was similar to that obtained from the AGR2. Both of studies showed that although PSA was consistent to be a prognostic marker, it partially reflected the degree of malignancy of the carcinomas in these groups of patients. 
From these results, S100A4 was expressed in higher levels in highly malignant prostate cell lines and tissues compared with the normal and BPH cases. Although the increased S100A4 expression was significantly associated with the increased malignancy of the carcinoma, it was not significantly associated with the reduced survival time of patients. Therefore, the increased expression of S100A4 may be used as a valuable biomarker to differential malignant phenotype but not suitable to be used as a prognostic marker to predict the outcome of patients with prostate cancer. 
To further address the question of whether S100A4 can be used as a therapeutic target for prostate cancer, we employed the RNA interference (RNAi) method in an attempt to deplete the expression of S100A4 in cultured prostate cells. RNAi is the most commonly used technique to suppress gene expression in a variety of cancers. In human periodontal ligament (PDL) cells, inhibition of S100A4 by siRNA resulted in increased expression of osteoblastic markers such as OPN and osteocalcin and the osteoblast-specific transcription factors, Runx2/Cbfa1 and Osterix266.The specific knockdown of S100A4 by siRNA suppressed cell growth, induced G2 arrest and eventual apoptosis and decreased cell migration in pancreatic cancer. The additional microarray analyses showed the knockdown of S100A4 induced expression of the tumour suppressor genes PRDM2 and VASH1 261. S100A4 expression was downregulated by RNAi in HEC-1A cells in endometrial cancer which resulted in significant reduction of migration and invasion. TGF-β1-mediated endometrial cancer cell motility was inhibited by S100A4 siRNA suggested S100A4 was upregulated by the TGF-β1 signalling pathway 267.
In this study, the plasmid-based RNAi suppressed S100A4 expression in DU145 prostate cancer cells were performed in both transient and stable manners. The best suppressing sequence was identified using the transient manner (Fig 4.5.1) and several clones were established by using the stable and long-term manner (Fig 4.5.2). Most of them were confirmed a decrease in S100A4 protein expression over three months (Fig 4.5.2). SDC11 and SDC2 which had the reduction of 4 and 28 fold were selected to do the further assessment. 
In this study, suppression of S100A4 were associated with a 11.4 and 3.5 fold decrease in anchorage-independent growth (Fig 4.6.1) and 4.9 and 1.6 fold decrease in invasiveness (Fig 4.6.2) in vitro, respectively, in the S100A4-highly-suppressed cells SDC2 and S100A4-moderately-suppresseed cells SDC11. Importantly, it was demonstrated that these phenotypic differences are independent of cellular proliferation as the rate of growth is conserved between sR-control and SDC2 and SDC11 (Fig 4.6.3). This suppression of S100A4 expression seemed not to be associated with the cellular motility (Fig 4.6.4). Stable S100A4 knockdown clones were generated by siRNA in HEC-1A cells, it also caused significant decreases in cell migration and invasion and no significant effect were observed on cell proliferation in vitro in endometrial cancer267.  
It has been proposed that S100A4 promoted the cell invasiveness through the cooperation of molecules MMP-9, TIMP-1.100, 130 









































CHAPTER FIVE: Result 3 – Osteopontin (OPN)

5.1. OPN expression in prostate cell lines

A single OPN band with a size of 64kD was detected by Western blot in all cell lines examined (Fig 5.1A) and the detailed quantitative measurements of relative OPN levels expressed in different cell lines were shown in Fig 5.1B. When the level of OPN expressed in the PNT2 cells was set at 1.0, the relative levels of OPN expressed in weakly malignant cell line LNCaP, highly malignant cell lines DU145 and PC3 were 1.5±0.3, 2.9±0.5 and 4.4±0.6, respectively.

5.2.	OPN expression in prostate tissues

The immunohistochemical staining of the different prostate tissues with the OPN-specific monoclonal antibody (MAb) was performed, as shown in Fig 5.2. The stain was located in the cytoplasm of the epithelial cells of the prostatic glands in most of the tissues. In some normal (Fig 5.2A) and BPH (Fig 5.2B) tissues, weak staining was observed in basal cells whereas in carcinoma tissues (Fig5.2 C-E), it was not seen since basal cells were absent. As represent in Fig 3.2F, a strongly stain was observed in a malignant carcinoma (large arrow) while it was negative in the adjacent benign areas (small arrow) within the same tissue sample. When the OPN-specific MAb was neutralized with the recombinant OPN protein, staining was blocked completely (Fig 5.2G and H). The results were summarized in Table 5.1. Amongst 116 cases studied, 3 (30%) of the 10 normal cases were unstained and the other 7 (70%) exhibited a weakly positive stain. Amongst 36 BPH samples, 32 (89%) stained weakly positive and 4 (11%) were unstained. The difference of OPN stains between normal and BPH cases was not statistically significant (two-sided Fisher’s exact test, p=0.16). Amongst 70 carcinomas samples, 31 (44%) stained strongly positive and 20 (29%) stained moderately positive while 19 (27%) stained weakly positive and no samples were unstained. The intensity of the staining in carcinomas is significantly stronger than that in normal (Chi-square test, p<0.001) and in BPH (Chi-square test, p< 0.001) tissues. 
Table 5.1 OPN expression in different prostate tissues
Tissues	Stain  Intensities	No. of cases
	Negative(-)No. (%)	Weak(+)No. (%)	Moderate(++)No. (%)	Strong(+++)No. (%)	
 Normal	3 (30%)	7 (70%)	0	0	10
BPH	4 (11%)	32 (89%)	0	0	36
Carcinoma(Total)	0	19 (27%)	20 (29%)	31 (44%)	70
GS<5	0	17 (85%)	2 (10%)	1 (5%)	20
GS5-7	0	4 (13%)	14 (47%)	12 (40%)	30
GS8-10	0	0	 2 (10%)	18 (90%)	20

5.3.	Correlations with patient survival

5.3.1.	OPN expression and patient survival

The relationship between the intensity of OPN staining and the patient-survival time are shown in Fig 5.3A. The 70 carcinomas were divided into weakly positive (+), moderately positive (++) and strongly positive (+++) groups (Table 5.1), according to their OPN staining intensities. The mean expected survival time for patients with weakly positive OPN stains was 61.6 months. The mean survival time for patients with moderately positive OPN stains and strongly positive OPN stains were reduced to 48.56 and 38.47 months, respectively. The survival of patients in moderately OPN positive cases was shorter than that in the weakly OPN positive cases, but the difference was not significant (log rank test, p=0.26). The survival of the patients in the strong OPN positive cases was significantly shorter than that in weakly OPN positive cases (log rank test, p=0.008) but the difference in survival between the strong and the moderate OPN positive cases was not significant (log rank test, p=0.19).

5.3.2.	Combined Gleason Scores (GS) and patient survival

To assess the relationship between the combined GS and patient survival, 70 carcinoma cases were divided into the weakly malignant group with GS of <5, the moderately malignant group with GS of 5-7 and the highly malignant group with GS of 8-10. The mean survival time of patients with weakly, moderately and highly malignant carcinomas was 66.2, 48.24 and 31.42 months, respectively (Fig 5.3B). The reduced survival time was significantly (log rank test, p=0.001) associated with the increased degree of malignancy. There was a highly significant difference between patients of highly malignant group and those of weakly malignant group in the length of the survival time (log rank test, p=0.003). The difference in survival time between the highly malignant cases and moderately cases was significant (log rank test, p=0.02), but difference between the weakly malignant cases and the moderately malignant cases was not significant (log rank test, p=0.09). 

5.3.3.	Prostate-Specific Antigen (PSA) and patient survival

The correlation between PSA level and patient-survival time was shown in Fig 5.3C. The median survival time for patients with low (<4ng/ml) and borderline (4-10ng/ml) PSA level was 48 months and it was also 48 months in patients with high (>10ng/ml) PSA levels. Although survival time has been reduced in patients with high PSA level, the association of the patient PSA level with the length of the survival time was not significant (log rank test, p=0.903).

5.3.4.	Androgen receptor (AR) and patient survival

The correlation between AR and survival time was shown in Fig 5.3D. Although the median survival time for patients with low (index<4) and high (index≥4) AR levels was 60 and 24 months, respectively, the time of patient survival and the level of AR were not significantly (log rank test, p=0.152) associated.

5.4.	Correlation between differently selected variables

5.4.1.	OPN expression and Combined Gleason Scores (GS)

Amongst 20 GS<5 carcinomas, 17(85%) stained weakly positive and 2 (10%) stained moderately positive and 1 (5%) stained strongly positive. Amongst 30 GS5-7 carcinomas, 4 (13%) stained weakly positive, 14 (47%) stained moderately positive and 12 (40%) stained strongly positive. Amongst 20 GS 8-10 carcinomas, none was unstained or stained weakly positive, 2 (10%) stained moderately positive and 18 (90%) stained strongly positive (Table 5.1). The intensity of the stains in moderately positive malignant cases is significantly stronger than that observed in the weakly malignant cases (Chi-square test, p<0.001). The intensity of the stains in the highly malignant case is significantly stronger than those observed in both the weakly malignant group (Chi-square test, p<0.001) and the moderately malignant group (Chi-square test, p<0.01).

5.4.2.	OPN expression and Prostate-Specific Antigen (PSA) level

The correlation between levels of PSA and OPN expression was shown in Fig 5.4A. For patients with weak, moderate and strong OPN stains, the median PSA level was 5.2, 12.5 and 9.2ng/ml, respectively. Box plot analysis showed that the level of PSA in the patients with moderate OPN staining was significantly (Mann-Whitney U test, p=0.019) higher than that of patients with weak staining. However, the difference in patient PSA levels between moderate and strong OPN stained groups (Mann-Whitney U test, p=0.224) and between weak and strong OPN stained groups (Mann-Whitney U test, p=0.259) were not significant.

5.4.3.	OPN expression and Androgen receptor (AR) index

The correlation of AR index with OPN expression was shown in Fig 5.4B. For patients with weak OPN stains, the median AR index was 2. For patients with moderate and strong OPN stains, the median AR indexes were 4. Box plot analysis showed that the difference in patient AR indexes either between strong and moderate OPN stained groups (Mann-Whitney U test, p=0.368), or between weak and moderate stained groups (Mann-Whitney U test, p=0.055), was not significant. The difference in patient indexes between weak and strong OPN stained groups was significant (Mann-Whitney U test, p=0.011).

5.4.4.	Prostate-Specific Antigen (PSA) and Combined Gleason Scores (GS)

The correlation of PSA levels and GS was shown in Fig 5.4C. For patients with GS≤5, GS6-7 and GS 8-10 carcinomas, the median PSA levels were 7.5, 6.2 and 20ng/ml, respectively. Box plot analysis showed that the PSA level was significantly higher in patients with GS 8-10 carcinomas than those with GS≤5 (Mann-Whitney U test, p=0.024) and GS 6-7 carcinomas (Mann-Whitney U test, p=0.027). However, the difference in patient PSA levels between the GS 6-7 and GS≤5 carcinoma groups was not significant (Mann-Whitney U test, p=0.911).

5.5.	RNA interference stably decreased OPN expression

PC3 prostate cells are highly malignant and expressing high levels of OPN as shown in Fig 5.1. RNAi was used to suppress OPN in PC3 cells specifically.

5.5.1.	Selection of efficient siRNA for OPN suppression

Three 21-nt sequences within the OPN cDNA for RNAi were selected and used to make double-stranded 21-nt siRNA constructs encoding sense and antisense siRNA. These three siRNAs were transient transfected to the PC3 cell line both separately and in different combined manners as described in Methods. After 72 hours, the transient transfectants were subjected to Western blot analysis for their OPN expression level. SiRNA 1 exhibited the highest efficiency in suppressing OPN expression. It reduced the OPN expression by nearly 5 fold from the level detected in the parental PC3 cells (Fig 5.5.1). Thus, siRNA1 was identified as the most efficient OPN suppressor. 

5.5.2.	Establishment of OPN stably suppressed clones

The plasmid express siRNA1 against OPN-cDNA target was designed and constructed as described in Methods. Sense and antisense siRNA sequences were arranged sequentially to facilitate the formation of hairpin siRNA upon transcription. PC3 cells were transfected with purified pSilencerTM 4.1-CMV neo vector containing either the siRNA1 insert or the scrambled siRNA control insert. pSilencerTM 4.1-CMV neo vector contains a neomycin resistance gene. The selection medium (RSM) containing 1mg/ml neomycin G418 was applied 24 hrs after transfection. Three months after the initial transfection, several clones in which the OPN expression was suppressed were established. They were named OPN-suppressed-PC3 clone (OPC) 1, OPC2, OPC3…etc, respectively. Western blot was performed to detect their OPN expression as shown in Fig 5.5.2. Result showed that the level of OPN in clone OPC7 and OPC2 had been moderately and highly suppressed by 3.8 and 29 folds, respectively, compared with sR-control transfectant. Thus, OPN-moderately-suppressed clone OPC7 and OPN-highly-suppressed clone OPC2 were chosen for further investigation. 

5.6.	Effect of suppression of OPN on tumor cells in vitro

5.6.1.	Suppression of OPN significantly inhibited anchorage-independent growth of  cancer cells

The soft agar colony-formation assay was performed to investigate the effect of OPN suppression on anchorage-independent growth of PC3 cells. As shown in Fig 5.6.1, no significant differences (student’s t test, p=0.49) were observed between the number of colonies formed by the parental PC3 cells and the scrambled-RNA transfectant (sR-control).  Numbers of colonies produced in soft agar by OPN-highly-suppressed cells OPC2 (student’s t-test, p<0.002) and OPN-moderately-suppressed cells OPC7 (student’s t-test, p<0.003) were significantly reduced by 44 and 8 folds, respectively, in comparison with sR-control.

5.6.2.	Suppression of OPN had no effect on cellular proliferation

Cell proliferation assay was performed in 6 days (144 h) to measure the growth rate for OPC clones. The density of cultured cells was determined by extrapolating from the standard curve and cell numbers were obtained by MTT assays as described in Methods. Cell proliferation rates of OPC2 (student’s t-test, p=0.8) and OPC7 (student’s t-test, p=0.19) did not show any significant difference from sR-control (Fig 5.6.2). 

5.6.3.	Suppression of OPN significantly inhibited the invasiveness of the cancer cells

The invasiveness of OPC clones were assessed using Matrigel coated transwell invasion chambers as described in Methods. While no significant (student’s t test, p=0.93) difference between parental PC3 cells and sR-control cells was observed, the invasiveness of OPC2 (student’s t-test, p<0.003) and OPC7 (student’s t-test, p<0.004) were reduced by 29 and 16 folds respectively, in comparison with sR-control (Fig 5.6.3B). The proportions of invaded cells into matrigel from PC3, sR-control, OPC2 and OPC7 were shown in Fig 5.6.3A.

5.6.4.	Suppression of OPN significantly inhibited the motility of cancer cells

The motility of OPC clones were assessed across transwell polycarbonate membranes as described in Methods. The parental PC3 cells and the sR were used as controls. Although the motility of PC3 cells and sR-control cells were significantly (student’s t test, p<0.01) different, the motility of OPC2 (student’s t-test, p<0.001) and OPC7 (student’s t-test, p<0.001) were reduced by 3.9 and 4 fold respectively, in comparison with sR-control (Fig 5.6.4B). The proportions of motile cells in PC3, sR-control, OPC2 and OPC7 were shown in Fig 5.6.4A.

5.7.	Cross suppression of OPN and S100A4 in SDC and OPC clones





The aim of the work described in this chapter was to establish whether or not OPN could be the prognostic biomarker for prostate cancer and if it plays a role in the malignant progression of prostate cancer. 
Some part of this work had been performed by this laboratory previously268, and was expanded in this study. 
Expression of OPN in prostate cell lines and tissues were investigated in this work and the expression status of this protein was correlated with the patient survival data. The expression of OPN was knocked down in the malignant prostate cancer cell line PC3 and the role of OPN in the malignancy was assessed in vitro.
OPN was first described in 1979 by Senger as a phosphoprotien secreted by transformed, malignant epithelial cells150. It is a secreted glycoprotein that is rich in aspirate and sialic acid residues and contains several functional domains155. OPN expression was first correlated with tumorgenecity by molecular cloning in 1989151. OPN was then found expressed and secreted by a variety of cancers. It functions in cell adhesion, chemotaxis, macrophage-directed interleukin-10 suppression, stress-dependent angiogenesis, prevention of apoptosis and anchorage-independent growth of tumour cells by regulating cell-matrix interactions and cellular signalling through binding with integrin and CD 44 receptors.152
Elevated OPN expression was also associated with the prognosis in cancers of the breast, stomach, lung, liver and colon145. OPN levels in tumors from 154 patients with lymph node negative (LNN) breast cancer who were followed for a median of 7 years were examined and the elevated OPN expression was associated with the poor clinical outcome229. A group of 333 patients with operable stage I and stage II breast cancer with 19 years of follow-up were studied and OPN-negative group had a median survival of >228 months while the OPN-positive group had a median survival of only 68 months234. Furthermore, serial osteopontin plasma levels in women with metastatic breast cancer were measured throughout the course of their disease. It enhanced the prognostic value with an increase OPN expression of >250 ng/mL having the most prognostic value for poor survival.237
In contrast to the well-studied role of OPN in breast cancer, the role of OPN in prostate cancer was not well studied. They were even controversial among different studies on the biological function of OPN149, 217, 218.
OPN was found contributing to prostate cancer progression by performing mRNA blot analysis and immunohistochemistry in human prostate cancer specimens and western blot analysis in prostate cell lines and it was successfully proved that OPN stimulated anchorage-independent growth of the prostate cancer cell lines LNCaP and C4-2 in vitro. It suggested OPN may act as a mediator of prostate cancer growth and progression.217 Prostate tissues from 34 patients with primary prostate cancer were assessed using immunohistochemistry and it also showed that enhanced OPN expressed in metastatic clinical samples.218 However, in that same study, it reported that OPN expression was not correlated with patients’ survival218 which was in contrast with another study 225. TRAMP mice model was also set on the study of OPN in prostate cancer and it demonstrated that dietary genistein delay the malignancy progression by inhibiting OPN expression in prostate cancer224. 
Although OPN was expressed in all 4 cell lines examined in our study (Fig 5.1), the level of OPN in the weakly malignant cell line LNCaP was 1.5-fold higher than that detected in the benign PNT-2 cells. A further increase of 2.9- and 4.4-fold, respectively, was found in the highly malignant cell lines DU145 and PC3. Western blot also detected nearly a 6-fold of increment of OPN expression in the highly malignant tissues when compared with those expressed in the normal and BPH samples268 (data was not shown). Thus, in the prostate cell lines and tissues examined the expression of OPN protein appears to be closely linked to the malignant potential of the cells. OPN may, therefore, be involved in malignant transformation and hence play an important role in pathogenesis of prostate cancer.
The immunohistochemical examination (Table 5.1) showed that there was no significant difference (Fisher's exact test, p = 0.16) in OPN staining intensities between the normal and the BPH samples. However, the level of OPN staining in carcinoma tissues was significantly stronger than those observed in both normal (Chi-square test, p < 0.001) and BPH (Chi-square test, p < 0.001) tissues. This result suggests that the increase in OPN expression in prostate tissue is related to prostate cancer only, and not to benign prostatic conditions, indicating that the elevated OPN expression may be an important factor enabling malignant transformation of the prostate cells. Further study (Table 5.1) on the correlation of the staining intensities and the degree of malignancy of the carcinoma tissues showed that the OPN intensity in moderately malignant prostate tissues were significantly (Chi-square test, p < 0.001) higher than that observed in the weakly malignant tissues. The OPN stain intensity observed in highly malignant prostate tissues (GS8-10) was significantly higher than those observed in both the weakly (GS<5) (Chi-square test, p < 0.001) and moderately (GS5-7)(Chi-square test, p < 0.01) malignant tissues. These results suggest that the elevated OPN expression is closely associated with increased GS of the carcinomas, indicating the increase in OPN expression may play an important role in malignant progression of prostate cancer. The fact that the increase in OPN staining intensity from weakly to moderately malignant samples is larger than that from moderately to highly malignant tissues, maybe due to a threshold value for OPN, which promotes the malignant progression of prostate cancer, and once this threshold value is surpassed, any further increase of GS is accompanied by a reduced increment of OPN expression.
When the relationship between the OPN staining intensity and the patient survival (Fig 5.3A) was assessed, a general inverse trend between a reduction in patient survival and increasing OPN staining intensity was observed (Log rank test, p = 0.03). Thus, the level of immunostaining for OPN may be used as a tool in the diagnosis and prognosis of prostatic biopsies. When similar assessment was made to examine the relationship between the GS and patient survival, it was found (Fig 5.3B) that the combined GS is significantly related to the mean survival of the patients (Log rank test, p = 0.001).
In present work, although the survival time was reduced with increased PSA level (Fig 5.3C), the increased PSA level was not significantly (log Rank test, p=0.903) associated with the reduced patient survival time. Thus, in this group of patients studied, PSA level was not a reliable prognostic marker. It also showed there was no significant (log Rank test, p=0.152) association between AR index and the time of patient survival (Fig 5.3D).
When the correlations between OPN expression and PSA level (Fig 5.4A) and between OPN and AR index (Fig 5.4B) were assessed, the level of PSA in the patients with moderate OPN staining was significantly higher than that of the patients with weak staining (Mann-Whitney U test, p=0.017) while the difference in patient PSA levels between strong OPN stains and weak (Mann-Whitney U test, p=0.26) and moderate (Mann-Whitney U test, p=0.224) stains were not significant. Similarly, the difference in patient AR indexes was neither significant between strong and moderate OPN stained cases (Mann-Whitney U test, p=0.368), nor between moderately and weakly stained cases (Mann-Whitney U test, p=0.06) while it was significant between weakly and strongly stained cases (Mann-Whitney U test, p=0.011). These results suggest that the expression of OPN was neither related to that of PSA nor to that of AR index in the cases of prostate cancer studied in this work, although OPN was reported dependent on Estrogen Receptors (ER) ER alpha for its expression in breast cancer269. More study is required to find out why OPN acts in such a different manner in breast and prostate cancers.  
In this set of cases studied, the assessment (Fig 5.4C) showed that PSA level was significantly higher in patients with highly malignant carcinomas than those with weakly (Mann-Whitney U Test, p=0.024) and moderately (Mann-Whitney U Test, p=0.027) malignant carcinomas, whereas the difference between the moderately and weakly malignant carcinoma cases was not significant (Mann-Whitney U Test, p=0.911). Similar to the results showed in AGR2 and S100A4 studies, it also showed that although PSA is not suitable to be a prognostic marker, it can partially reflect the degree of malignancy of the carcinomas in these groups of patients. 
These results demonstrated that both Gleason score and the OPN staining intensities of the carcinomas were significantly associated with patient survival while neither of the PSA and AR was associated with patient survival. Thus, both OPN stain and GS can be used as prognostic factors for prostate cancer patients. 
Our study on OPN in prostate cancer has proved that the expression of OPN in the carcinoma tissues was significantly increasing comparing to the normal and BPH samples and it was associated with the Gleason Score of the carcinoma which indicated OPN was involved in the malignant transformation of prostate epithelial cells. Meanwhile, from these 116 cases examined in our study, the elevated expression of OPN was associated significantly with the reduced survival time of patients, which suggested OPN was an important determinant for patient survival and could be served as molecular marker for prostate cancer progression. 
To further address the question of whether OPN can be used as a therapeutic target for prostate cancer, we employed the RNA interference (RNAi) method in an attempt to deplete the expression of OPN in cultured prostate cells. RNAi is the most commonly used technique to suppress gene expression in a variety of cancers. OPN knockdown in murine lung cancer 3LL cells resulted in the decrease of MPE accumulation in mice and markedly decreased Vascular endothelial growth factor (VEGF) concentration in Malignant pleural effusion (MPE) which suggested that OPN is positively involved in the formation of MPE of lung cancer presumably by promoting VEGF secretion from vascular endothelial cells or mesothelial cells270. In the human gastric cancer cells, down-regulation of OPN inhibited anchorage-independent growth, migration and invasion through the reduction of MMP-2 and uPA expression, inhibition of NF-kappaB DNA binding activity, and down-regulation of Akt phosphorylation271. The specific knockdown of OPN by siRNA in breast cancer suppressed the expressions of oncogenic molecules such as uPA, MMP-2 and -9 resulting in inhibition of in vitro cell motility and reduced the pristine-induced tumour growth and angiogenesis in vivo272.
In this study, the plasmid-based RNAi suppressed OPN expression in PC3 prostate cancer cells were performed in both transient and stable manners. The best suppressing sequence was identified using the transient transfection (Fig 5.5.1) and several clones were established by using the stable transfection (Fig 5.5.2). Most of these clones expressed reduced OPN level over three months (Fig 5.5.2). OPC2 which exhibited a 29 fold reduction were selected to study the effect of the suppression. To avoid the clonal variation, another clone OPC7 which had the moderate suppression by 3.8 fold was also used to detect the effect of the suppression.
In this study, suppression of OPN were associated with a 44 and 8 fold decrease in anchorage-independent growth (Fig 5.6.1) and 29 and 16 fold decrease in invasiveness (Fig 5.6.3) in vitro, respectively, in the OPN-highly-suppressed cells OPC2 and OPN-moderately-suppressed cells OPC7. Importantly, it was demonstrated that these phenotypic differences are independent of cellular proliferation as the rate of growth is conserved between sR-control and OPC2 and OPC7 (Fig 5.6.2). Unlike the S100A4 suppression in DU145 cells, OPN-suppressed-PC3 clones OPC2 and OPC7 had a significant reduction by 3.9 and 4 folds on cellular motility, respectively, in comparison with sR-control (Fig 5.6.4). 
These results were supported by several other studies on the suppression of OPN in other cancers. The suppression of OPN expression by siRNA also exhibited the inhibition of the anchorage-independent growth, invasiveness and motility in the gastric BGC-823 cells271. In human endometrial endothelial cells (HEEC) and human endometrial cancer Ishikawa (ISK) cells, OPN expression was knocked down by siRNA resulting in the reduced cell migrationand decreased invasiveness of both HEECs and ISK cells while no effect on the proliferative activity273. Cell motility and invasiveness were decreased only in OPN-suppressed clones in colon cancer while the proliferation was similar amongst the cell lines274. 
It has been proposed that OPN promotes anchorage-independent growth, cell motility and invasiceness via the pathways involving the cooperation of molecules, like MMP-9, NF-kappa-B, pro-MMP-2, COX-2 etc. 144, 184, 189, 190 
Both of S100A4-suppressed SDC clones and OPN-suppressed OPC clones showed their suppression in the anchorage-independent growth and invasiveness. In the final part of the study described in this chapter, possible relationship between S100A4 and OPN were explored using Western blot to test the S100A4 and OPN expression in SDC, OPC, sR cells. While in S100A4-suppressed clones, OPN expression level decreased with the S100A4 expression decrease, the reverse trend happened in the OPN-suppressed clones where S100A4 expression level decrease with the OPN expression level increase. This result indicated that S100A4 may be upstream mediator of OPN and it plays an important role in carcinogenesis through mediating of modulate OPN in prostate cancer.



























































CHAPTER SIX: Result 4- OPN suppression in DU145 malignant cell line

Result 5.7 suggested that OPN can be the downstream mediator for S100A4. To avoid further arguments on the study of exploring the relationship between these two genes, S100A4 and OPN were suppressed in the same malignant prostate cell line DU145 in which both S100A4 and OPN expressed at a high level. S100A4 suppression in DU145 was shown in Chapter Four. OPN suppression in DU145 malignant cell line were shown as below.

6.1	Establishment of OPN-suppressed-DU145 (ODC) clones

The plasmid express siRNA1 against OPN-cDNA target used in Chapter 5 was stably transfected into DU145 cells as described in Methods. Three months after the initial transfection, several clones in which the OPN expression was suppressed were established. They were named OPN-suppressed-DU145 clone (ODC) 1, ODC2, ODC3…etc, respectively. Western blot was performed to detect their OPN expression as described in Fig 6.1. Result showed that the level of OPN in clone ODC10 was almost completely suppressed and it was suppressed moderately by 8 folds in ODC4, compared to sR-control transfectant. Thus, OPN-moderately-suppressed clone ODC4 and OPN-highly-suppressed clone ODC10 were chosen for further investigation. 

6.2	Effect of suppression of OPN on DU145 cells in vitro.

6.2.1	Suppression of OPN significantly inhibited anchorage-independent growth of DU145 cells

The soft agar colony-formation assay was performed to investigate the effect of OPN expression on anchorage-independent growth of DU145 cells. As shown in Fig 6.2.1, no significant differences (student’s t test, p=0.14) were observed between the number of colonies formed by the parental DU145 cells and the scrambled-RNA transfectant (sR-control). Numbers of colonies produced in soft agar by OPN-highly-suppressed cells ODC10 (student’s t test, p<0.0001) and OPN-moderately-suppressed cells ODC4 (student’s t test, p<0.001) were significantly reduced by 13.6 and 2.6 folds, respectively, in comparison with sR-control.

6.2.2	Suppression of OPN had no effect on cellular proliferation

Cell proliferation assays were performed in 144 h to measure the growth rate for SDC clones. The density of cultured cells was determined by extrapolating from the standard curve and cell numbers were obtained by MTT assays as described in Methods. No significant difference was observed either between sR-control with ODC4 (student’s t test, p=0.77) or sR-control with ODC10 (student’s t test, p=0.4).

6.2.3	Suppression of OPN significantly inhibited the invasiveness of DU145 cells

The invasiveness of ODC clones were assessed using Matrigel-coated transwell invasion chambers as described in Methods. While no significant (student’s t test, p=0.75) difference between parental DU145 cells and sR-control cells was observed, the invasiveness of ODC4 (student’s t test, p<0.0001) and ODC10 (student’s t test, p<0.003) were reduced by 14 and 8.5 folds respectively, in comparison with sR-control (Fig 6.2.3B). The proportions of invaded cells into Matrigel from DU145, sR-control, ODC4 and ODC10 were shown in Fig 6.2.3A.

6.2.4	Suppression of OPN had no effect on cellular motility





In this study, the plasmid-based RNAi suppressed OPN expression in DU145 prostate cancer cells were performed. Several clones were established after three months (Fig 6.1). Most of them were confirmed a decrease in OPN protein expression (Fig 6.1). OPN-highly-suppressed clone ODC10 and OPN-moderately-suppressed clone ODC4 were selected for further assessment. 
Suppression of OPN were associated with a 13.6 and 2.6 fold decrease in anchorage-independent growth (Fig 6.2.1) and 14 and 8.5 fold decrease in invasiveness (Fig 6.2.3) in vitro, respectively, in the OPN-highly-suppressed cells ODC10 and OPN-moderately-suppressed cells ODC4. It was also demonstrated that these phenotypic differences are independent of cellular proliferation as the rate of growth is conserved between sR-control and ODC10 and ODC4 (Fig 6.2.2). Similarly to the result obtained from the SDC clones, but contrast to that from the OPC clones, neither ODC4 (student’s t test, p=0.300) nor ODC10 (student’s t test, p=0.137) showed any significantly difference on cellular motility, in comparison with sR-control (Fig 6.2.4B). 

































CHAPTER SEVEN: Result 5- Effect of suppression of OPN and S100A4 in tumorgenecity in vivo  





The control, ODC and SDC cells produced tumors in all nude mice (100% tumor incidence). Tumors appeared in six days in all experimental mice after the inoculation. The volume of the five groups did not exhibit any difference until Day 13 from which the tumor of control group and SDC2 group started to grow faster than the other groups. Tumors from OPN-suppressed groups, ODC4 and ODC10, remarkably grew in a slower rate than those from the control group. Tumors produced by OPN-moderately-suppressed ODC4 grew slower that those in OPN-highly-suppressed ODC10 group. Tumors produced by S100A4-moderately-suppressed SDC11 group grew in the lowest rate during the post-inoculation days amongst all these groups although S100A4-highly-suppressed SDC2 group did not produce any reduction to the sR-control. 
On the 23rd day of the post-inoculation days, the average volume of tumors produced by the control cells was 347.9±38.8mm3. The average volume of tumors produced by the group inoculated by ODC4 and ODC10 were 102.2±26.5 mm3 and 204.9±53.6 mm3 respectively. The average volume of tumors in ODC4 group and ODC10 group was significantly reduced by 3.4 (student’s t test, p<0.001) and 1.7 (student’s t test, p<0.01) folds, respectively, in comparison with those in the control group (Fig 7.1B). The average volume of tumors produced by the group inoculated by SDC11 was 62.8±12.5 mm3, significantly reduced by 5.6 (student’s t test, p<0.0001) fold in comparison with the control group. However, the average volume of tumors produced from SDC2 group was 330.8±80mm3, not significantly (student’s t test, p=0.84) different from the control group. Moreover, between two OPN-suppressed groups, the tumors produced by OPN-highly-suppressed ODC10 cells were significantly (student’s t test, p<0.05) larger at nearly 2 times than those produced by OPN-moderately-suppressed ODC4 cells. Between two S100A4-suppressed groups, tumors produced by S100A4-highly-suppressed SDC2 cells was significantly (student’s t test, p<0.003) larger at nearly 5.3 times than those produced by the S100A4-moderately-suppressed SDC11 cells. Fig 7.1C showed the representative tumors taken from each group of mice. 

7.2	S100A4 and OPN expression in tumor tissues by Western blot

Protein was extracted from the tumors produced by control, ODC and SDC cells as described in Methods. Western blot was used to detect the expression level of OPN and S100A4. All data were summarized and the quantitative measurements of relative average OPN and S100A4 expressed in the tumors from different groups of animals were shown in Fig 7.2. When the average level of OPN and S100A4 were both set at 1, the relative levels of OPN expressed in ODC4, ODC10, SDC2 and SDC11 were 0.4±0.12, 0.53±0.09, 0.95±0.38 and 0.16±0.05, respectively. Expression of OPN in the groups of animals inoculated with ODC4, ODC10 and SDC11 were reduced by 2.5, 1.9 and 6.3 fold, respectively, in comparison with that in control group. Expression of OPN was not significantly (student’s t test, p=0.91) reduced in SDC2 group compared to that in control group. The relative level of S100A4 expressed in ODC4, ODC10, SDC2 and SDC11 groups were 0.49±0.14, 0.4±0.04, 0.33±0.09 and 0.58±0.07, reduced by 2, 2.5, 3 and 1.7 fold, in comparison with that in control group. 

7.3	S100A4 and OPN expression in tumor tissues by Immunohistochemistry

Examples of Immunohistochemical stains of tumor tissues with OPN and S100A4 antibodies were shown in Fig 7.3. When stained with OPN antibody, strongly stains were observed in control group (Fig7.3A) and samples stained moderately positive in ODC4 and ODC10 groups. In SDC2 group, it stained strongly positive and in SDC11 group, only weakly positive stains were observed (Fig 7.3A).When stained with S100A4 antibody, it stained strongly positive in control group (Fig 7.3B) and it stained moderately positive and weakly positive in ODC4 group and ODC10 group respectively. Weakly positive stains were observed in SDC2 group while moderately positive stains were shown in SDC11 group (Fig 7.3B).

7.4	Correlations between the average volumes of tumor and protein expression levels from tumor

7.4.1	Correlation between the average volumes of tumor and OPN levels expressed in tumor

The correlation of the average volumes of tumors and OPN expression levels was shown in Fig 7.4.1. It showed the average tumor volumes were significantly associated with the levels of OPN expressed in each group of animals.  

7.4.2	Correlation between the average volumes of tumors and S100A4 levels expressed in tumors

The correlation of the average volumes of tumors and S100A4 expression levels was shown in Fig 7.4.2. It showed the average tumor volumes were not significantly associated with the levels of S100A4 expressed in each group of animals. 
 
7.4.3	Correlation between OPN expression level and S100A4 expression levels in tumors





The aim of this chapter was to investigate the effect of the reduced OPN or S100A4 on the tumorgenecity of prostate cancer cells in vivo and hence to assess whether OPN or S100A4 can be used as a therapeutic target for prostate cancer. 
Animal groups inoculated by OPN-moderately-suppressed ODC4, OPN-highly-suppressed ODC10 and S100A4-moderately-suppressed SDC11 cells produced suppressions in tumor growth of ~3, ~2 and ~5 folds respectively, compared to the group inoculated by the control cells (Fig 7.1A). However, the animal group inoculated by S100A4-highly-suppressed SDC2 did not show any difference in tumor growth from that in control group.
Tumor volumes were measured at the end of experiment as shown in Fig 7.1B. In comparison with the control group, the average volume of tumors from the groups inoculated with OPN-moderately-suppressed ODC4 and OPN-highly-suppressed ODC10 were significantly (student’s t test, p<0.001 and p<0.01) reduced by 3.4 and 1.7 fold, respectively.  The average volume of tumors from the group inoculated with S100A4-modertely-suppressed SDC11 was significantly (student’s t test, p<0.0001) reduced by 5.6 fold, compared with the control group, but that inoculated with S100A4-highly-suppressed SDC2 did not have any reduction (student’s t test, p=0.84). 
Further analysis showed between the groups injected with ODC4 and ODC10, the tumors produced in the group injected with OPN-highly-suppressed ODC10 were significantly (student’s t test, p<0.05) 2 times larger than those produced in OPN-moderately-suppressed ODC4 group. Tumors produced in the group by S100A4-highly-suppressed SDC2 cells were significantly (student’s t test, p<0.003) larger, at 5.3 times, than those produced in the S100A4-moderately-suppressed SDC11 group, between two animal groups injected with SDC2 and SDC11.
Before injection, the level of OPN in OPN-highly-suppressed ODC10 cells was almost completely suppressed and it was suppressed moderately by 8 folds in OPN-moderately-suppressed ODC4 cells, compared to sR-control cells (Result 6.1). The level of S100A4 in S100A4-modertely-suppressed SDC11 cells and S100A4-highly-suppressed SDC2 cells were suppressed by 4 and 28 folds, respectively, compared with sR-control cells (Result 4.5.1). Generally, no relationship can be observed between the level of OPN suppression in ODC4 and ODC10 cells before the injection and the reduction of tumor volume in vivo. Similarly, the levels of S100A4 expression in SDC2 cells and SDC11 cells before the injection were not associated with the tumor volume in vivo. 
RNA interference was born in 1998, when it was demonstrated that small strands of RNA stuck together in pairs, like the strands that make up DNA, could turn off specific genes in roundworms275. This finding was honored by Nobel Prize in Physiology or Medicine in 2006276. It was widely used to suppress the expression of specific genes in a variety of studies277-279on different subjects, like virology, oncogenes, cancer therapy etc. However, the exact mechanism was not fully understood. Controversial results were reported by several labs280-282. It was recently names as ‘RNAa’, briefly for RNA activation, and these kinds of siRNA were identified leading to the activation of E-cadherin, p21, and VEGF in human cells283. Although siRNA was enormously successful as a laboratory tool, it is not sufficiently stable in vivo.
Although OPN expression and S100A4 expression were suppressed respectively in ODC and SDC cells by siRNA and the effect of the suppression were observed in vitro in this study, the quantitative suppression of OPN and S100A4 by siRNA can change after the injection in vivo.
In order to clarify the levels of OPN and S100A4 expression in vivo and the possible association with tumor volume, all tumor samples were subjected to Western blot and immunohistochemistry analysis to examine the OPN and S100A4 expression in these tumor tissues.
Results showed that in vivo, the level of OPN in the group inoculated by OPN-moderately-suppressed ODC4 cells was suppressed by 2.5 fold and it was suppressed by 1.9 fold in the group inoculated by OPN-highly-suppressed ODC10 cells, compared to that in the control group (Fig 7.2). In the group inoculated by S100A4-modertely-suppressed SDC11 cells, OPN levels were also reduced by 6.3 fold, compared to that in the control group. OPN level in the S100A4-highly-suppressed SDC2 group was not suppressed significantly, compared to that in the control group.   
In vivo, the level of S100A4 in the groups inoculated by ODC4, ODC10, SDC2 and SDC11 cells were significantly inhibited by 2, 2.5, 3 and 1.7 folds, compared to the control group. 
To compare the possible change of the suppression of OPN and S100A4 from in vitro to in vivo, the expression levels of OPN and S100A4 before injection and after injection were summarized in Table 7.1. 
Table 7.1 Expression of OPN and S100A4 and average tumor volume







Level of OPN expression in ODC4 cells before injection produced a suppression of 8 fold and exhibited a suppression of 2.5 fold in vivo, compare to that in the control. Level of OPN expression in ODC10 cells was suppressed completely before injection but only exhibited a suppression of 1.9 fold compared to that in control. As shown in Table 7.1, the group inoculated with OPN-highly-suppressed-moderately ODC10 cells expressed higher level of OPN, 1.3 times, than that with OPN-moderately-suppressed- ODC10 cells in vivo. The average tumor volume of the ODC10 group was 2 times larger that that of ODC4 group.
Level of S100A4 expressed in SDC2 cells before injection produced a tremendous suppression of 25 fold and show a suppression of 3 fold in vivo, compare to that in the control. Level of S100A4 expression in SDC11 cells was suppressed 4 fold before injection and exhibited a suppression of 1.7 fold compared to that in control. Although the group inoculated with S100A4-highly-suppressed SDC2 cells still expressed lower expression of S100A4, by 1.8 fold, in comparison with S100A4-moderately-suppressed SDC11 cells in vivo, the difference was not as significant as it was between the S100A4 expression in SDC2 and SDC11 cells before injection. (Table 7.1)
From above, it was suggested that RNAi was not stable in vivo in this study although generally groups of animals injected with OPN-suppressed cells did exhibit a suppression of OPN and those injected with S100A4-suppressed cells did show a suppression of S100A4 in vivo.
Immunohistochemistry analysis result shown in Fig 7.3 also supported the result obtained from Western blot analysis (Fig 7.2) for the levels of OPN and S100A4 expressed in tumors of different groups. 
When associating the levels of OPN and S100A4 expression in tumors with the average tumor volumes, interesting correlations were discovered. The suppression of OPN in tumors produced by ODC and SDC cells was significantly correlated to the average tumor volume in each group, indicating that tumor growth and tumor volume were inhibited by suppression of OPN expression and related to the concentration of OPN expressed in tumors (Fig 7.4.1). However, the suppression of S100A4 in tumors produced by cell lines was not associated with the average tumor volume in each group of animals (Fig 7.4.2), suggesting OPN but not S100A4 was the determinate for the tumorgenecity in vivo. 
From the In vitro assays (Result 5.7), it was suggested that S100A4 may be an upstream mediator of OPN which mediating through OPN. However, in vivo, Fig 7.4.3 showed increment of OPN expression was correlated with the decrease of S100A4 expression, which indicating S100A4 may be one of the upstream mediators which can only mediate the tumorgenecity through OPN in vivo. 































Chapter EIGHT: General discussion and conclusions

Prostate cancer, accounting for 24% of total cancer cases and caused 10,038 deaths, becomes the most common cancer in UK males in 2006. 
The molecular pathology of prostate cancer is complex. Great effort has been made to find out those genes promoting or suppressing malignant progression of prostate cancer and many new genes have been identified. In contrast to rapid development in identification of new oncogenes and tumor suppressor genes, progress in searching for new prognostic markers and therapeutic targets from cancer-related genes has been relatively slow. 
The overall aim of this thesis was to examine the possibility of using three candidate genes as prognostic markers and the potential therapeutic targets in prostate cancer. The identification of the prognostic and therapeutic significance of these genes can be of clinical importance. To achieve this aim, the work focused on two areas: firstly, assessment of the prognostic significance of these genes; secondly, investigation of the therapeutic potential of these genes.
AGR2, S100A4 and OPN were selected as the candidate genes because they were highly and universally expressed in a variety of cancers. In addition, they have shown their possible role of the prognosis and therapy potential in the breast cancer which is also the hormone responsible cancer like the prostate cancer. Expressions of these three genes have been observed in a variety of cancers. Their elevated expressions were reported in breast cancer. AGR2 was expressed at a higher level in the human breast cancer cell line MCF-7 than in the benign cell line Hama 12348. S100A4 protein expression appeared widely expressed in early and advanced breast cancer stages compared with normal breast when applying Immunohistochemistry to malignant and normal breast tissue cores from 216 patients284. Study on the primary tumors of 154 patients with lymph node negative (LNN) breast cancer examined by immunohistochemical analysis and in situ hybridization revealed the overexpression of OPN protein and mRNA229. Furthermore, these three genes have some similarities in the structure and mechanism and some possible relationships have been suggested between them in playing the role in prostate cancer. Little was investigated on AGR2 in prostate cancer. Controversial results were shown in studies on S100A4 and OPN due to the poor sample size and inefficient methodology. It is of great importance for prostate prognosis and treatment to characterize these molecules for their roles in prostate cancer.

8.1.	Expression of AGR2, S100A4 and OPN in prostate cancer cells and tissues.

Status of AGR2, S100A4 and OPN expression were examined in several commonly used prostate cell lines using western blot analysis. Increased expressions of all these three proteins were found in the highly malignant cells, indicating they may be involved in the malignancy progression of prostate cancers. The immunohistochemistry analyses was applied to the prostate tissue samples of patients and significant increase in the levels of AGR2 ,S100A4 and OPN expression was observed in carcinomas compared to normal and BPH cases, suggesting that  AGR2, S100A4 and OPN can be an indicator for the malignant progression of prostate cancer.

8.2.	AGR2 and OPN were associated with the patients survival

Overall increased AGR2 and OPN expression was significantly associated with the poor prognosis in terms of patient survival, respectively, indicating level of immunostaining of AGR2 and OPN may be used as a tool in the diagnosis and prognosis of prostatic biopsies. Although the median survival time for patients with positive S100A4 stains was 12 months shorter than those stained negatively this difference was not statistically significant suggesting the S100A4 stain intensity increment may not be used to accurately predict the patient outcome. 
Reliable prognostic biomarkers are always of clinical importance. Studies on prognostic biomarkers for prostate cancer have identified several potential molecules for their predictive value. However, none of them can replace PSA. PSA is still used as a standard tool in practical diagnosis for prostate cancer. In recent years, more and more controversies in PSA use were revealed, especially focus on the cutpoint of PSA levels between ‘normal’ and ‘abnormal’ which was usually 4.0ng/ml34, 35. Recently, it was evident that when data on the PSA level and prostate cancer were analyzed during five-year intervals at a hospital, PSA levels were only associated with prostate weight from 1998 to 2003 while serum PSA was correlated with prostate stage, grade and size from 1983 to 198836. Obviously, more reliable and consistent biomarker should be valued and considered.
This study suggested that AGR2 and OPN may be potential prognostic biomarkers for prostate cancer in this study. 

8.3.	Both OPN and S100A4 suppressed tumor cells in vitro

RNAi was used to suppress S100A4 expression in DU145 prostate cancer cells and OPN expression in PC3 cells. Long-term S100A4-suppressed-DU145 (SDC) clones and OPN-suppressed-PC3 (OPC) clones were established. SDC2 and SDC11 were chosen to investigate the effect of suppression of S100A4 as representative S100A4-highly-suppressed and S100A4-moderately-suppressed clones to avoid colonel variation. OPC2 and OPC7 were selected in the same purpose. Soft-agar assays, proliferation assays, invasion and motility assays were performed to examine the effect of the suppression to the anchorage-independent growth, proliferation, invasiveness and motility of cancer cells. The results showed that although high expression of S100A4 was not significantly associated with poor prognosis, the suppression of S100A4 did reduce the anchorage-independent growth and invasiveness of the prostate cancer cells. High expression of OPN was not only significantly associated with poor prognosis, but the suppression of OPN also did reduce the anchorage-independent growth, invasiveness and cellular motility of the prostate cancer cells. Since both of S100A4-suppressed SDC clones and OPN-suppressed OPC clones showed their suppression in the anchorage-independent growth and invasiveness, relationship between S100A4 and OPN were explored using Western blot. Result indicated that S100A4 may be upstream mediator of OPN and it plays an important role in carcinogenesis through mediating of modulate OPN in prostate cancer.
To detect the effect of the suppression of S100A4 and OPN more accurately, OPN-suppressed-DU145 clones were also established. In vitro assays were carried on the OPN-highly-suppressed clone ODC10 and OPN-moderately-suppressed clone ODC4. It was demonstrated that the suppression of OPN in DU145 did reduce the anchorage-independent growth and invasiveness of the prostate cancer cells, like that observed in S100A4.
RNAi is a successful lab tool in suppressing gene expression since it was discovered in 1998275. It has been used to test the hypotheses of gene function, functional screening and target identification, target validation and therapeutics245. siRNA, short interference RNA, was originally identified in the RNA interference pathway but the endogeous siRNAs have been identified in plants, fungi and animals. It was adopted in this study to silence the S100A4/OPN expression in prostate cancer cells. Result showed that RNAi did silencing the protein expression in cancer cells.
Anchorage-independent growth, proliferation, invasiveness and motility, these are four important capabilities for cancer cells during the tumor development, especially invasiveness. The capability for invasion and metastasis enables cancer cells to escape the primary tumor mass and colonize new terrain in the body where nutrients and space are not limiting at least initially285. It was suggested S100A4 modulate the invasiveness of tumor cells through inhibiting of PKC and CK2 dependent phosphorylation of nonmuscle myosin96, 116 and thus increasing the myosin solubility, suppressing its assembly and directly destabilizing myosin filaments117. Compared to S100A4, the pathway OPN involved in invasiveness is much more complicated. Several studies showed that OPN activated pro-MMP-2 via an NF-kappa-B mediated pathway during ECM invasion184, 188. It was also shown that OPN induction on NF kappa B activity and uPA secretion was PI3’-kinase/Akt/iKK mediated189. MMP-9, was reported to be activated by OPN through MAPK/IKKalpha/beta-dependent NIK/NFκB mediated pathway, thus regulating the invasiveness191.Thus, OPN activated MMP through several overlapping pathways145.

8.4.	OPN, not S100A4 suppressed the tumorgenecity in vivo

Assessment of effect of the reduced expression of S100A4 and OPN on the ability of forming tumours of cancer cells in vivo were performed to investigate whether S100A4 or OPN can be used as a therapeutic target. OPN, not S100A4, was found playing a determinate role on the tumor growth and tumor volume in this study. It was revealed that the tumor growth and tumor volume were inhibited by suppression of OPN expression and related to the concentration of OPN expressed in vivo, suggesting that OPN can be used as a therapeutic target for prostate cancer.
OPN contributed to prostate cancer progression217, 218 and associated with the clinical data, especially patient survival225. Recently, most mechanism studies were  focused on the role of OPN-mediated MMP activation in prostate cancer progression223, 227. It suggested that the OPN pathway play a vital key role in prostate cancer progression. 
Not only in prostate cancer cells, OPN is expressed and secreted by various other cells, and has a role in cell adhesion, chemotaxis, prevention of apoptosis, invasion, migration and anchorage-independent growth of tumor cells in a variety of cancers286. Since OPN acts an oncogenic molecule in cancers, it was suggested that silencing the OPN message by RNAi may be useful approach for treatment of cancer162.

The work presented in this thesis has established several important findings:
Firstly, the overexpression of AGR2, S100A4, OPN in malignant cancer cells and tissues suggested all of them were involved in the malignancy of prostate cancer.
Secondly, elevated AGR2 or OPN expression were associated with the poor patient survival, suggesting AGR2 and OPN can be used as a prognostic biomarker for prostate cancer.
Thirdly, suppression of S100A4 or OPN can inhibited the anchorage-independent growth and invasiveness in prostate cancer cells in vitro.
Fourthly, in vivo, suppression of OPN expression inhibited tumor growth and tumor volume and the concentration of OPN expressed in tumor were associated with the average tumor volume, suggesting that OPN can be used as a therapeutic target for prostate cancer.
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DNA Annealing Solution                                  
Nuclease-free water                                            
pSilencer 4.1-CMV neo                                   
siPORT XP-1 Transfection Agent                       
siPORT NeoFX Transfection Agent      
BD Biosciences, Erembodegem, Belgium
     BD Matrigel  
BDH, England, UK
 Acetone    
     Absolute ethanol
Bio-Rad Laboratories GmbH, Munchen, Germany      
Bio-Rad protein assay (Dye reagent)       
Biosera, East Sussex, UK                                       
Foetal bovine serum (FBS)                      
BIOzym, Germany    
Agarose                                  
  BWR international, London, UK      
      Haematoxylin solution
      HCl
      Hydrogen peroxide            




Polyclonal Rabbit Anti-Human S100A4
Polyclonal Swine Anti-Rabbit Immunoglobulins/HRP     
Polyclonal Rabbit Anti-Mouse Immunoglobulins/HRP   
 Developmental Studies Hybridoma Bank (DSHB), Iowa, USA
MPIIIB10 ascites (OPN)
Fisher Scientific, Loughborough, UK
Methanol        
Tryptone
Yeast Extract            
  Flowgen Bioscience, Nottingham, UK                                             
protoFlowGel      
  Fluka, Switzerland
      Isopropanol  
 FMC Bioproducts, Philadelphia, USA                                                 
Low melting temperature agarose (LMA)      
 GE Healthcare, Buckinghamshire,UK
     Amersham ECL Western Blotting Detection Reagent  
     Amersham Hybond ECL Nitrocellulose Membrane
     Amersham Hyperfilm ECL
 GENTA Environmental Ltd, Tockwith, UK
    IMS
    Xylene
Gibco, Invitrogen, Paisley, UK
PBS Tablets        
2.5% Trypsin (10X)                                       
Versene (1X)                                              
Fungizone (amphotericin B 250UG/ml)   
Opti-MEM I medium                                       
 Lonza, Belgium
L-Glutamine (200mM)                              
Pen-strep (5000U penicillin/ml, 5000U streptomycin/ml) 
ProSieve color protein marker                          
 Melford, UK
Tris base ultrapure                                                    
Glycine                                                                     
Sodium Chloride                 
 Microm, Bicester, UK
     Para gard                                   
National Diagnostics, Hessle, UK
 ProtoBlock
New England Biolabs, Hitchin, UK     
10×Buffer for T4 DNA ligase                            
T4 DNA ligase                                                   
BamHI                                                               
Hind III                                                               
10×NEBuffer 2                                                   
100×purified BSA (for restriction enzyme reaction)     
  PAA, Pasching, Austria
RPMI1640 
G418 sulfate      
QIAGEN, Crawley, UK
    QIAprep Spin Miniprep Kit
    QIAGEN Plasmid Midi kit
Promega, Southampton, UK
    Ethidium bromide
Roche, England, UK
    DNA marker III
    DNA marker XIV 
  Severn Biotech Ltd, UK
      Collodial Coomassie blue stain                                                                          
 Sigma, USA





















Sodium dodecyl sulphate (SDS)
NNN’N’-tetramethylethylenediamine (TEMED)
    Testosterone                                        
Sigma-Aldrich, Germany 
Dimethyl sulphoxide (DMSO)                   
    Tween 20           
    GBX developer and replenisher    




Sodium hydroxide                            
                  





































Routine Medium (RM)                                       
RPMI1640 (1X)                                   500ml
L-Glutamine                                     20mM 
Pen-strep                                          5ml 
FBS                                             10% (v/v) 
*if LNCap, add hormone: 25ul Hydrocortisone and 25ul Testosterone in 5ml PBS

Routine Selective Medium (RSM)                    
RM with 0.1% G418    

Serum-free Medium (SFM)                                
RPMI1640 (1X)                                   500ml
L-Glutamine                                      20mM 
Pen-strep                                           5ml 
BSA                                             0.01%    
  
Freezing Medium (FM)                                                  
RM/RSM with 7.5% DMSO 

PBS
1 PBS tablet dissolved in 500ml distilled water (Autoclave)

Trypsin/EDTA solution (T/E)                                            




10% (w/v) SDS solution                               
10g SDS dissolved in 100ml distilled water

1.5M Tris-HCl pH8.8 solution                
27.23g Tris base in 150ml distilled water(Adjust PH to 8.8)

0.5M Tris-HCl pH6.8 solution                       
6g Tris base in 100ml distilled water(Adjust PH to 6.8)

10%(w/v) APS solution                                 
0.1g APS powder in 1ml distilled water (made fresh before use)

SDS-PAGE seperating gel (9%, 12%, 15%) 10ml     
                  9%             12%              15%
Distilled water             4.4ml           3.5ml            2.4ml
ProtoFlowGel              3ml              4ml             5ml
1.5M TRIS pH 8.8 solution   2.5ml           2.5ml            2.5ml
10% SDS solution          100μl           100μl            100μl
10% APS solution          100μl           100μl            100μl
TEMED                  5μl               5μl              5μl
  
SDS-PAGE stacking gel (4%) 10ml                       
Distilled water                                      6.1ml
ProtoFlowGel                                      1.3ml           
0.5M TRIS pH 6.8 solution                            2.5ml
10% SDS solution                                   100μl
10% APS solution                                   100μl
TEMED                                           10μl

Electrophoresis buffer (Running Buffer)                                               
Tris base                                         50mM
Glycine                                         192mM 
SDS                                           0.1% (w/v)

 
Transferring Buffer (made fresh before use)                                           
Tris base                                          25mM
Glycine                                          192mM 
Methanol                                        20% (v/v) 

5×SDS-PAGE sample loading buffer(SLB)            
1M Tris-HCl PH6.8                                 1.25ml
40% glycerol                                        15ml 
10%SDS                                            5ml 
β-mercaptoethanol                                  1.25ml 
1% Bromophenol blue                                2.5ml  

2×SDS-PAGE sample loading buffer(SLB)            
0.5M Tris-HCl PH6.8                               1.25ml
Glycerol                                           2.5ml 
10%SDS                                            2ml 
β-mercaptoethanol                                   0.5ml 
1% Bromophenol blue                                200ml 
Distilled water                                      3.55ml 

1×sample loading buffer (SLB) 
2×SLB                                         1ml 900μl
β-mercaptoethanol                                   100μl





Reagent A                                           5g 
Reagent B                                         10ml 
Distilled water                                    up to 100ml

TBS buffer (10×)
Tris base                                          60.55g
Sodium Chloride                                    87.66g 
Distilled water                                     up to 1 litre
 (Adjust PH to 7.5)

0.05%TBS-Tween (TBST) 
500ul Tween20 in 1litre TBS (1×)

Amersham ECL Western Blotting Detection Reagent
Diluted Developer                                          
110ml GBX developer and replenish add distilled water to 500ml
Diluted Fixer 
110ml GBX developer and replenish add distilled water to 500ml

Diluted Dye Reagent





EDTA                                                3.72g
Sodium hydroxide                                      0.32g
Distilled water                                    up to 1 litre






Hydrogen peroxide                                      12ml
Methanol                                             400ml

1%acid/alcohol                                                      
HCl                                                   20ml
IMS                                                 1400ml
Distilled water                                          600ml

Scott’s Tap Water
Magnesium sulphate                                       20g
Sodium bicarbonate                                       3.5g
Distilled water                                          up to 1 litre

2%APES                                                                    
20ml APES in 1000ml acetone

5% BSA/TBS                                                               




SOB medium  
Tryptone                                               2% (w/v)
Yeast extract                                           0.5% (w/v) 
NaCl                                                 0.585g
KCl                                                  0.1864g 
Distilled water                                       up to 1 litre
  (Adjust PH to 7.0)

2M Mg2+ salts 
1M MgCl2                                              (20.31g)
1M MgSO4                                                                    (24.65g)
Distilled water                                        up to 100ml
  (Sterile by filtration)

RF1 Buffer (1 litre)                                                  
KCl                                                     7.456g
MgCl.4H2O                                                9.9g
KAc                                                     2.94g
CaCl2                                                    1.5g
Glycerol                                               15% (v/v) 
Distilled water                                         up to 1 litre
  (Adjust PH to 5.8, Sterilize by filtration)
                
RF2 Buffer 
MOPS                                                    2.10g
KCl                                                      0.745g
CaCl2.2H2O                                                11.0g
Glycerol                                                   15% (v/v) 
Distilled water                                           up to 1 litre
 (Adjust PH to 6.8, Autoclave)
               
LB medium                                               
10g LB Broth in 500ml distilled water
 (Autoclave)

LB-Agar                                                                  
17.5g LB Agar in 500ml distilled water
 (Autoclave)

LB-Amp agar                                                         
100µl/ml Ampicillin in made LB-Agar                                                                                     

LB-Amp medium (made fresh)                              
100µl/ml Ampicillin in made LB medium                                                                                       

SOC medium (5ml, made fresh)                      
SOB Medium                                               4.85ml
2M Mg2+ Salt solution                                          50µl
Glucose                                                     20% 

Glycerol stock for bacteria
Glycerol	                                				     5 ml
Bacteria culture				                                 3 ml
LB medium					                                 4 ml

2% agarose gel                                            
1g Agarose in 50ml 0.5×TBE

TBE (10x)                                                         
Tris base                                                       108g
Boric acid                                                       55g
0.5M EDTA PH8.0                                               40ml
Distilled water                                              up to 1litre


B6: In vitro assay

MTT solution (5mg/ml)                                
50mg MTT powder in 10ml PBS       

2% LMA                                                          






Appendix C: Equipments 
(sequenced as brands)

BD Falcon, BD Bioscience, Oxford, UK
Cell Scraper   
BD Microlance 3, Ireland                                                      
Needles                       
BD Plastics, Sunderland, UK
Syringes
BECTON DIKINSON, USA
Sterile falcon 2059 tube         
Bandelin, Berlin                      
Sonicator 
Bibby Sterlin Ltd, Stone, UK
Disaposable plastic pipettes                     
Bio-RAD, Hemel, UK
Mini-protein 3 cell system
Mini Trans-Blot Electrophoretic Transfer Cell
UV transilluminator








25 ml Universal tubes
50 ml PP tubes                    
Leitz Labovert, Luton, UK                  
Microscope












Tissue culture petri dishes 
Nalgene, UK
Cryobox 




QIA Shredder spin column
Scientific Laboratory Supplies Ltd, Nottingham, UK
BD cell Inserts        
haemacytometer 
Magnificent stirrer
Swann-Morton, Sheffield, UK   
Carbon steel surgical blades 22  
Surgipath, UK 
Micro slides              
Shandon UK, London, UK
Sequenza casstte and special cover plates 
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